<SEC-DOCUMENT>0001178913-23-000811.txt : 20230301
<SEC-HEADER>0001178913-23-000811.hdr.sgml : 20230301
<ACCEPTANCE-DATETIME>20230301093141
ACCESSION NUMBER:		0001178913-23-000811
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		5
CONFORMED PERIOD OF REPORT:	20230301
FILED AS OF DATE:		20230301
DATE AS OF CHANGE:		20230301

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Sol-Gel Technologies Ltd.
		CENTRAL INDEX KEY:			0001684693
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			L3
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38367
		FILM NUMBER:		23690153

	BUSINESS ADDRESS:	
		STREET 1:		7 GOLDA MEIR ST.
		STREET 2:		WEIZMANN SCIENCE PARK
		CITY:			NESS ZIONA
		STATE:			L3
		ZIP:			7403648
		BUSINESS PHONE:		97289313433

	MAIL ADDRESS:	
		STREET 1:		7 GOLDA MEIR ST.
		STREET 2:		WEIZMANN SCIENCE PARK
		CITY:			NESS ZIONA
		STATE:			L3
		ZIP:			7403648
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>zk2329314.htm
<DESCRIPTION>6-K
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Z-K GLOBAL
         Document created using Broadridge PROfile 23.1.1.5115
         Copyright 1995 - 2023 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;">
  <div>
    <div style="line-height: 1.25;">
      <div style="text-align: center; line-height: 1.25; font-weight: bold;">
        <hr align="center" style="border: none; border-bottom: 1px solid black; border-top: 4px solid black; height: 10px; color: #ffffff; background-color: #ffffff; margin-left: auto; margin-right: auto;"><br style="line-height: 1.25;">
        <br>
        <font style="background-color: rgb(255, 255, 255); font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 14pt; font-style: normal; font-variant: normal; text-transform: none;">UNITED STATES</font></div>
      <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-size: 14pt; font-weight: bold; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">SECURITIES AND EXCHANGE COMMISSION</div>
      <div style="text-align: center; line-height: 1.25; font-weight: bold;">Washington, D.C. 20549</div>
    </div>
    <div style="line-height: 1.25;">
      <div style="line-height: 1.25;">&#160;</div>
    </div>
    <div style="line-height: 1.25; background-color: rgb(255, 255, 255); font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 14pt; font-style: normal; font-variant: normal; text-transform: none;">
      <div style="text-align: center; line-height: 1.25;">FORM&#160;6-K</div>
    </div>
    <div style="line-height: 1.25;">
      <div style="line-height: 1.25;">&#160;</div>
    </div>
    <div style="line-height: 1.25;">
      <div style="text-align: center; line-height: 1.25; font-weight: bold;">Report of Foreign Private Issuer</div>
      <div style="text-align: center; line-height: 1.25; font-weight: bold;">Pursuant to Rule&#160;13a-16&#160;or&#160;15d-16</div>
      <div style="text-align: center; line-height: 1.25; font-weight: bold;">Under the Securities Exchange Act of 1934</div>
    </div>
    <div style="line-height: 1.25;">
      <div style="line-height: 1.25;">&#160;</div>
    </div>
    <div style="line-height: 1.25;">
      <div style="text-align: center; line-height: 1.25; font-weight: bold;">For the month of March 2023</div>
    </div>
    <div style="line-height: 1.25;">
      <div style="line-height: 1.25;">&#160;</div>
    </div>
    <div style="line-height: 1.25;">
      <div style="text-align: center; line-height: 1.25; font-weight: bold;">Commission File Number 001-38367</div>
    </div>
    <div style="line-height: 1.25;">
      <div style="line-height: 1.25;">&#160;</div>
    </div>
    <div style="line-height: 1.25;">
      <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-size: 16pt; font-weight: bold; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">SOL-GEL TECHNOLOGIES LTD.</div>
      <div style="text-align: center; line-height: 1.25;">(Translation of registrant&#8217;s name into English)</div>
    </div>
    <div style="line-height: 1.25;">
      <div style="line-height: 1.25;">&#160;</div>
    </div>
    <div style="line-height: 1.25;">
      <div style="text-align: center; line-height: 1.25; font-weight: bold;">7 Golda Meir Street</div>
      <div style="text-align: center; line-height: 1.25; font-weight: bold;">Ness Ziona 7403650, Israel</div>
      <div style="text-align: center; line-height: 1.25;">(Address of principal executive offices)</div>
    </div>
    <div style="line-height: 1.25;">
      <div style="line-height: 1.25;">&#160;</div>
    </div>
    <div style="line-height: 1.25;">
      <div style="text-indent: 24.5pt; line-height: 1.25;">Indicate by check mark whether the registrant files or will file annual reports under cover Form&#160;20-F&#160;or Form&#160;40-F.</div>
    </div>
    <div style="line-height: 1.25;">
      <div style="line-height: 1.25;">&#160;</div>
    </div>
    <div style="line-height: 1.25;">
      <div style="text-align: center; line-height: 1.25;">Form&#160;20-F <font style="font-family: 'Segoe UI Symbol', sans-serif;">&#9746;</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Form&#160;40-F&#160;<font style="font-family: 'Segoe UI Symbol', sans-serif;">&#9744;</font></div>
    </div>
    <div style="line-height: 1.25;">
      <div style="line-height: 1.25;">&#160;</div>
    </div>
    <div style="line-height: 1.25;">
      <div style="text-indent: 24.5pt; line-height: 1.25;">Indicate by check mark if the registrant is submitting the Form&#160;6-K&#160;in paper as permitted by Regulation&#160;S-T&#160;Rule 101(b)(1):&#160;&#160;<font style="font-family: 'Segoe UI Symbol', sans-serif;">&#9744;</font></div>
    </div>
    <div style="line-height: 1.25;">
      <div style="line-height: 1.25;">&#160;</div>
    </div>
    <div style="line-height: 1.25;">
      <div style="text-indent: 24.5pt; line-height: 1.25;">Indicate by check mark if the registrant is submitting the Form&#160;6-K&#160;in paper as permitted by Regulation&#160;S-T&#160;Rule 101(b)(7):&#160;&#160;<font style="font-family: 'Segoe UI Symbol', sans-serif;">&#9744;</font></div>
    </div>
    <div style="line-height: 1.25;">
      <div style="line-height: 1.25"><br style="line-height: 1.25;">
        <br>
        &#160;</div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="text-align: center; line-height: 1.25; font-weight: bold;">INFORMATION CONTAINED IN THIS REPORT ON FORM 6-K</div>
    </div>
    <div style="line-height: 1.25;">
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="line-height: 1.25;">Attached hereto and incorporated by reference herein are the following documents:</div>
      <div style="line-height: 1.25;">&#160;</div>
    </div>
    <div style="line-height: 1.25;"><a href="exhibit_99-1.htm">Exhibit 99.1: Notice and Proxy Statement for the Special Meeting of Shareholders of the Registrant scheduled for
        March 30, 2023.</a></div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="line-height: 1.25;"><a href="exhibit_99-2.htm">Exhibit 99.2:&#160; Proxy Card.</a></div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="line-height: 1.25;">
      <div style="line-height: 1.25;">This Form 6-K and related exhibits are hereby incorporated by reference into the Company's Registration Statement on Form S-8 (Registration No. 333-223915) and its Registration Statement on Form F-3 (Registration No.
        333-264190).</div>
    </div>
    <div style="line-height: 1.25;">
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="line-height: 1.25; text-align: center;">&#160;2</div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="line-height: 1.25;">&#160;</div>
    </div>
    <div style="line-height: 1.25;">
      <div style="text-align: center; line-height: 1.25; font-weight: bold;">SIGNATURES</div>
    </div>
    <div style="line-height: 1.25;">
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-indent: 24.5pt; line-height: 1.25;">Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</div>
    </div>
    <div style="line-height: 1.25;">
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
    </div>
    <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="zf0566b8f069a4c7b97bc6615df9e2e37">

        <tr>
          <td style="width: 50%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td colspan="2" style="vertical-align: top;">
            <div style="line-height: 1.25; font-weight: bold;">SOL-GEL TECHNOLOGIES LTD.</div>
          </td>
        </tr>
        <tr>
          <td style="width: 50%; vertical-align: middle;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 4%; vertical-align: middle;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 46%; vertical-align: middle;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 50%; vertical-align: top;">
            <div style="line-height: 1.25;">Date:&#160; March 1, 2023</div>
          </td>
          <td style="width: 4%; vertical-align: top;">
            <div style="line-height: 1.25;">By:</div>
          </td>
          <td style="width: 46%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
            <div style="line-height: 1.25;">/s/ Gilad Mamlok</div>
          </td>
        </tr>
        <tr>
          <td style="width: 50%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 4%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 46%; vertical-align: top;">
            <div style="line-height: 1.25;">Gilad Mamlok</div>
          </td>
        </tr>
        <tr>
          <td style="width: 50%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 4%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 46%; vertical-align: top;">
            <div style="line-height: 1.25;">Chief Financial Officer</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;">
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="line-height: 1.25">
        <div style="text-align: center;">&#160;3</div>
        <hr align="center" style="border: none; border-bottom: 4px solid black; border-top: 1px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;"></div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
    </div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>exhibit_99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Z-K GLOBAL
         Document created using Broadridge PROfile 23.1.1.5115
         Copyright 1995 - 2023 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;">


  <div>
    <div style="text-align: justify; line-height: 1.25;">
      <hr align="center" style="border: none; border-bottom: 1px solid black; border-top: 4px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;"></div>
    <div style="text-align: right; line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><u><font style="font-weight: bold;">Exhibit 99.1</font></u><br>
      <br>
    </div>
    <div style="text-align: center; line-height: 1.25;"><img width="199" height="95" src="image00001.jpg"></div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;">SOL-GEL TECHNOLOGIES LTD.</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: center; line-height: 1.25;">7 Golda Meir St., Weizmann Science Park, Ness Ziona, 7403650, Israel</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: center; line-height: 1.25;">+972-8-931-3433</div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;">________________________________</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;">NOTICE OF SPECIAL MEETING OF SHAREHOLDERS</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;">TO BE HELD ON MARCH 30, 2023</div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;">________________________</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; line-height: 1.25;">Dear Sol-Gel Technologies Ltd. Shareholders:</div>
    <div style="text-align: justify; line-height: 1.25;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">We cordially invite you to attend a Special Meeting of Shareholders, or the Meeting, of Sol-Gel Technologies Ltd., or
      the Company, to be held at 4:00 p.m. (Israel time) on Thursday, March 30, 2023, at our offices at 7 Golda Meir St., Weizmann Science Park, Ness Ziona, Israel.</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">The Meeting is being called for the following purposes:</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <table cellspacing="0" cellpadding="0" id="z4c2310f23eaf4bb39d9a435a4c1899d6" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 5.22%; vertical-align: top;">
            <div style="text-align: right; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">(1)&#160;&#160;&#160;&#160;&#160; <br>
            </div>
          </td>
          <td style="width: 94.78%; vertical-align: top;">
            <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">To approve a private placement to M. Arkin Dermatology Ltd., the Company&#8217;s controlling shareholder; and</div>
            <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman',Times,serif;"> <br>
            </div>
          </td>
        </tr>
        <tr>
          <td style="width: 5.22%; vertical-align: top;">
            <div style="text-align: right; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">(2)&#160;&#160;&#160;&#160;&#160; <br>
            </div>
          </td>
          <td style="width: 94.78%; vertical-align: top;">
            <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">To approve the renewal of the Registration Rights Agreement between the Company and M. Arkin Dermatology Ltd.</div>
          </td>
        </tr>

    </table>
    <div style="text-align: justify; text-indent: 35.45pt; line-height: 1.25;"> <br>
    </div>
    <div style="text-align: justify; text-indent: 35.45pt; line-height: 1.25;">The Company is currently unaware of any other matters that may be raised at the Meeting. Should any other matters
      be properly raised at the Meeting, the persons designated as proxies shall vote according to their own judgment on those matters.</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Our Board of Directors unanimously recommends that you vote in favor of each of the above proposals, which are
      described in the attached Proxy Statement.</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Shareholders of record at the close of business on Monday, February 27, 2023<font style="font-weight: bold;">&#160;</font>are entitled to notice of and to vote at the Meeting.</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Whether or not you plan to attend the Meeting, it is important that your shares be represented and voted at the
      Meeting. Accordingly, after reading the Notice of Special Meeting of Shareholders and accompanying Proxy Statement, please mark, date, sign and mail the enclosed proxy or voting instruction form as promptly as possible. If voting by mail, the proxy
      must be received by Broadridge Financial Solutions, Inc. ("<font style="font-weight: bold;">Broadridge</font>") or at our registered office at least 48 hours (or such shorter period as
      the Chairman of the Meeting may determine) prior to the appointed time of the Meeting to be validly included in the tally of ordinary shares voted at the Meeting. An earlier deadline may apply to receipt of your voting instruction form, if indicated
      therein. Detailed proxy voting instructions are provided both in the Proxy Statement and on the enclosed proxy card and voting instruction form. Proxies may also be executed electronically via by utilizing the control number sent to you. Shareholders
      who hold their shares in street name may be able to utilize the control number sent to them to submit their voting instruction to their brokers, trustees or nominees by other means, if so indicated on their voting instruction form. An electronic copy
      of the enclosed proxy materials is also available for viewing at http://ir.sol-gel.com/.</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; line-height: 1.25;">Sol-Gel Technologies Ltd.</div>
    <div style="text-align: justify; line-height: 1.25;"> <br>
    </div>
    <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br>
    </div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: center; line-height: 1.25;"><img width="199" height="95" src="image00001.jpg"></div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;">SOL-GEL TECHNOLOGIES LTD.</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: center; line-height: 1.25;">7 Golda Meir St., Weizmann Science Park, Ness Ziona, 7403650, Israel</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: center; line-height: 1.25;">+972-8-931-3433</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;">__________________________</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;">PROXY STATEMENT</div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;">__________________________</div>
    <div style="text-align: justify; line-height: 1.25;">&#160;</div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;">SPECIAL MEETING OF SHAREHOLDERS</div>
    <div style="text-align: justify; line-height: 1.25;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">This Proxy Statement is being furnished in connection with the solicitation of proxies on behalf of the Board of
      Directors (the &#8220;Board&#8221;), of Sol-Gel Technologies Ltd. (&#8220;Sol-Gel&#8221; or the &#8220;Company&#8221;), to be voted at a Special Meeting of Shareholders (the &#8220;Meeting&#8221;), and at any adjournment thereof, pursuant to the accompanying Notice of Special&#160; Meeting of
      Shareholders. The Meeting will be held at 4:00 p.m. (Israel time) on Thursday, March 30, 2023, at our offices at 7 Golda Meir St., Weizmann Science Park, Ness Ziona, Israel.</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">This Proxy Statement, the attached Notice of Special Meeting of Shareholders and the enclosed proxy card or voting
      instruction card are being made available on or about Wednesday, March 1, 2023 to holders of Sol-Gel ordinary shares.&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">You are entitled to receive notice of, and to vote at, the Meeting, if you hold ordinary shares as of the close of
      business on Monday, February 27 the record date for the Meeting. You can vote your shares by attending the Meeting or by following the instructions under &#8220;How You Can Vote&#8221; below. Our Board urges you to vote your shares so that they will be counted
      at the Meeting or at any postponements or adjournments of the Meeting.</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">&#160;</div>
    <div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold;">Agenda Items</div>
    <div style="text-align: justify; line-height: 1.25;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">The Meeting is being called for the following purposes:</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <table cellspacing="0" cellpadding="0" id="zc575892c78f045b08cef1763543cddac" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 5.22%; vertical-align: top;">
            <div style="text-align: right; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">(1)&#160;&#160;&#160;&#160;&#160;&#160; <br>
            </div>
          </td>
          <td style="width: 94.78%; vertical-align: top;">
            <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">To approve a private placement to M. Arkin Dermatology Ltd., the Company&#8217;s controlling shareholder; and</div>
            <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman',Times,serif;"> <br>
            </div>
          </td>
        </tr>
        <tr>
          <td style="width: 5.22%; vertical-align: top;">
            <div style="text-align: right; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">(2)&#160;&#160;&#160;&#160;&#160;&#160; <br>
            </div>
          </td>
          <td style="width: 94.78%; vertical-align: top;">
            <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">To approve the renewal of the Registration Rights Agreement between the Company and&#160; M. Arkin Dermatology Ltd.</div>
            <div style="line-height: 1.25;"><font style="line-height: 1.25;">&#160;</font></div>
          </td>
        </tr>

    </table>
    <div style="text-align: justify; text-indent: 35.45pt; line-height: 1.25;">The Company is currently unaware of any other matters that will come before the Meeting. Should any other matters
      be properly presented at the Meeting, the persons designated as proxies shall vote according to their own judgment on those matters.</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-style: italic; font-weight: bold;">Board Recommendation</div>
    <div style="text-align: justify; line-height: 1.25;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;"><font style="font-weight: bold;">Our Board unanimously
        recommends that you vote&#160;</font>&#8220;<font style="font-weight: bold;">FOR</font>&#8221;&#160;<font style="font-weight: bold;">each of the
        above proposals.</font></div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold;">Quorum</div>
    <div style="text-align: justify; line-height: 1.25;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">On February 27, 2023, we had&#160; 25,695,458 ordinary shares issued and outstanding. Each ordinary share outstanding as
      of the close of business on the record date, February 27, 2023, is entitled to one vote upon each of the proposals to be presented at the Meeting. Under our Articles of Association, the Meeting will be properly convened if at least two shareholders
      attend the Meeting in person or sign and return proxies, provided that they hold shares representing thirty three and one-third (33 1/3%) or more of our voting power. If a quorum is not present within half an hour from the time scheduled for the
      Meeting, the Meeting will be adjourned for one week (to the same day, time and place), or to a day, time and place determined by the Board of Directors (which may be earlier or later than said time). At such adjourned meeting the presence of any number of shareholders in person or by proxy (regardless of the voting power represented by their shares) will constitute a quorum for the business which the original Special Meeting was called.&#160;&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;"> <br>
    </div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <!--PROfilePageNumberReset%Num%2%%%-->
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold;">Vote Required for Approval of the Proposals&#160;</div>
    <div style="text-align: justify; line-height: 1.25;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">The affirmative vote of the holders of a majority of the voting power represented at the Meeting in person or by
      proxy and voting thereon (which excludes abstentions) is necessary for the approval of each of the proposals. Apart from for the purpose of determining a quorum, broker non-votes will not be counted as present and are not entitled to vote.</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">In addition, the approval of each of the proposals requires that either of the following two voting requirements be
      met as part of the approval by an ordinary majority of shares present and voting thereon:</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">&#160;</div>
    <table cellspacing="0" cellpadding="0" id="zb45ebd6f4c3347b1bfb9f96ea8d36a37" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 0.6%; vertical-align: top;">
            <div style="text-align: justify; line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 3.86%; vertical-align: top;">
            <div style="text-align: right; line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><font style="font-weight: bold;">&#9679;</font>&#160;&#160;&#160;&#160; <br>
            </div>
          </td>
          <td style="width: 95.54%; vertical-align: top;">
            <div style="text-align: justify; line-height: 1.25;">approval by a majority of the votes of shareholders who do not have a personal interest in the approval of the proposal that is
              voted at the Meeting, excluding abstentions; or</div>
            <div style="text-align: justify; line-height: 1.25;"> <br>
            </div>
          </td>
        </tr>
        <tr>
          <td style="width: 0.6%; vertical-align: top;">
            <div style="text-align: justify; line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 3.86%; vertical-align: top;">
            <div style="text-align: right; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#9679; &#160; &#160; <br>
            </div>
          </td>
          <td style="width: 95.54%; vertical-align: top;">
            <div style="text-align: justify; line-height: 1.25;">the total number of shares held by shareholders who do not have a personal interest in the proposal (as described in the
              previous bullet-point) that is voted against the proposal does not exceed two percent (2%) of the aggregate voting rights in our Company.</div>
          </td>
        </tr>

    </table>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">&#160;&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">A &#8220;personal interest&#8221; of a shareholder, for purposes of each of the proposals, is (1) a shareholder&#8217;s personal
      interest in the approval of an act or a transaction of the Company, including (i) the personal interest of any of his or her relatives (which includes for these purposes a shareholder&#8217;s spouse, siblings, parents, grandparents, descendants, and
      spouse&#8217;s descendants, siblings, and parents, and the spouse of any of the foregoing); (ii) a personal interest of a corporation in which a shareholder or any of his/her aforementioned relatives serves as a director or the chief executive officer,
      owns at least 5% of its issued share capital or its voting rights or has the right to appoint a director or chief executive officer; and (iii) a personal interest of an individual voting via a power of attorney given by a third party (even if the
      empowering shareholder has no personal interest), and the vote of an attorney-in-fact shall be considered a personal interest vote if the empowering shareholder has a personal interest, and all with no regard as to whether the attorney-in-fact has
      voting discretion or not, but (2) excludes a personal interest arising solely from the fact of holding shares in the Company.</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">&#160;</div>
    <div style="text-align: justify; text-indent: 35.45pt; line-height: 1.25;">Shareholders with&#160; a personal interest are qualified to participate in the vote on each of the proposals; however,
      the vote of such shareholders may not be counted towards the majority requirement described above and will not count towards the 2% threshold described in the second bullet point above.</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;"><font style="font-weight: bold;">A shareholder must
        inform our Company before the vote (or if voting by proxy, indicate on the proxy card) whether or not such shareholder has a personal interest, and failure to do so disqualifies such shareholder from participating in the vote on each of the
        proposals.</font>&#160;<font style="font-weight: bold;">If you believe that you, or a related party of yours, possesses a personal interest and you wish to participate in the vote on each of
        the proposals, you should indicate the existence of a personal interest on the enclosed proxy card or on the voting instruction form (if applicable) and should furthermore contact our Corporate Controller, Eyal Ben-Or, at +972-8-931-3437 or <u>Eyal.Ben-Or@sol</u>-gel.com, who will advise you as
        to how to submit your vote for that proposal. If you hold your shares in&#160;</font>&#8220;<font style="font-weight: bold;">street name</font>&#8221;<font style="font-weight: bold;">&#160;(i.e., shares that are held through a bank, broker or other nominee) and believe that you possess a personal interest in the approval of each of the proposals, you may also contact the representative
        managing your account, who could then contact our Corporate Controller on your behalf.</font></div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">&#160;</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-weight: normal; font-style: normal;" class="BRPFPageNumber">2</font></div>
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold;">How You Can Vote</div>
    <div style="text-align: justify; line-height: 1.25;">&#160;</div>
    <div style="text-align: justify; text-indent: 35.45pt; line-height: 1.25;">You can vote your shares by attending the Meeting or by completing and signing a proxy card or voting instruction
      form. If you are a shareholder of record, that is, your shares are registered directly in your name with our transfer agent, American Stock Transfer &amp; Trust Company, these proxy materials are being sent directly to you. The form of proxy card
      that has been sent to you can be completed, signed and returned in the envelope that was enclosed with it, or executed electronically via <u>www.proxyvote.com</u> by
      utilizing the control number sent to you.&#160; This provides the primary means for authorizing the voting of your ordinary shares without attending the Meeting in person. You may change your mind and cancel your proxy card by sending us written notice,
      by signing and returning a proxy card with a later date, or by voting in person or by proxy at the Meeting. We will not be able to count a proxy card unless we
      receive it at our principal executive offices at 7 Golda Meir St., Weizmann Science Park, Ness Ziona, 7403650, Israel, or Broadridge receives it in the enclosed envelope, not later than 6:59 a.m.&#160; (Israel time) on Thursday, March 30, 2023 or such
      shorter period prior to the Meeting as the Chairman of the Meeting may determine.</div>
    <div style="text-align: justify; text-indent: 35.45pt; line-height: 1.25;">&#160;</div>
    <div style="text-align: justify; text-indent: 35.45pt; line-height: 1.25;">If your ordinary shares are held in a brokerage account or by a trustee or nominee, you are considered to be the
      beneficial owner of shares held in &#8220;street name,&#8221; and these proxy materials are being forwarded to you together with a voting instruction form by the broker, trustee or nominee or an agent hired by the broker, trustee or nominee. Please follow the
      instructions provided by your broker, trustee or nominee to direct them how to vote your shares. Shareholders who hold their shares in street name may be able to utilize the control number appearing on their voting instruction form to submit their
      voting instruction to their brokers, trustees or nominees by other means, if so indicated on their voting instruction form. All votes should be submitted by 6:59 a.m. Israel time on Thursday, March 30, 2023 (11:59 p.m. Eastern Time on Wednesday,
      March 29, 2023), or such other deadline as may be indicated on the voting instruction form, in order to be counted towards the tally of ordinary shares voted at the Meeting (unless the Chairman of the Meeting extends that deadline). Alternatively, if
      you wish to attend the Meeting and vote in person, you must obtain a &#8220;legal proxy&#8221; from the broker, trustee or nominee that holds your shares, giving you the right to vote the shares at the Meeting.</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; text-indent: 35.45pt; line-height: 1.25;">If you provide specific instructions (by marking a box) with regard to the proposals, your shares will be voted as
      you instruct. If you sign and return your proxy card without giving specific instructions with respect to a particular proposal, your shares may be voted in favor of the proposals in accordance with the recommendation of the Board. However, if you
      are a beneficial owner of shares and do not specify how you want to vote on your voting instruction form, your broker will generally not be permitted to cast a vote with respect to that proposal (commonly referred to as a &#8220;broker non-vote&#8221;). In that
      circumstance, the shares held by you will be included in determining the presence of a quorum at the Meeting, but are not considered &#8220;present&#8221; for the purpose of voting on the relevant proposal. Such shares have no impact on the outcome of the voting
      on such proposal. If your shares are held of record by a bank, broker, or other nominee, we urge you to give instructions to your bank, broker, or other nominee as to how your shares should be voted so that you thereby participate in the voting on
      these important matters. In all cases, you must remember to indicate in writing and/or contact the Company if you have a personal interest in the approval of each of the proposals. If you sign and return your proxy card or voting instruction form,
      the persons named as proxies will vote in their discretion on any other matters that properly come before the Meeting.</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold;">Who Can Vote</div>
    <div style="text-align: justify; line-height: 1.25;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">You are entitled to receive notice of the Meeting and to vote at the Meeting if you are a shareholder of record at
      the close of business on Monday, February 27, 2023. You are also entitled to notice of the Meeting and to vote at the Meeting if you held ordinary shares through a bank, broker or other nominee that is one of our shareholders of record at the close
      of business on&#160; Monday, February 27, 2023, or which appear in the participant listing of a securities depository on that date.</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">&#160;</div>
    <div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold;">Revocation of a Proxy</div>
    <div style="text-align: justify; line-height: 1.25;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Shareholders may revoke the authority granted by their execution of proxies at any time before the effective exercise
      thereof by filing with us a written notice of revocation or duly executed proxy bearing a later date, or by voting in person at the Meeting. Unless otherwise indicated on the form of proxy, shares represented by any proxy in the enclosed form, if the
      proxy is properly executed and received by the Company at least 48 hours (or such shorter period as the Chairman of the Meeting may determine) prior to the Meeting, will be voted in favor of the proposal and any other matters that may be presented to
      the Meeting, as described above.</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;"> <br>
    </div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-weight: normal; font-style: normal;" class="BRPFPageNumber">3</font></div>
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">&#160;</div>
    <div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold;">Solicitation of Proxies</div>
    <div style="text-align: justify; line-height: 1.25;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Proxies are being distributed to shareholders on or about Wednesday, March 1, 2023. Certain officers, directors,
      employees, and agents of the Company, none of whom will receive additional compensation therefor, may solicit proxies by telephone, email, or other personal contact. We will bear the cost for the solicitation of the proxies, including postage,
      printing, and handling, and will reimburse the reasonable expenses of brokerage firms and others for forwarding material to beneficial owners of shares..</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">&#160;</div>
    <div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold;">Voting Results</div>
    <div style="text-align: justify; line-height: 1.25;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">The final voting results will be tallied by the Company&#8217;s Corporate Controller based on the information provided by
      the Company&#8217;s transfer agent or otherwise, and the overall results of the Meeting will be published following the Meeting in a report on Form 6-K that will be furnished to the U.S. Securities and Exchange Commission (the &#8220;<font style="font-weight: bold;">SEC</font>&#8221;).</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">&#160;</div>
    <div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold;">Availability of Proxy Materials</div>
    <div style="text-align: justify; line-height: 1.25;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Copies of the proxy card, the notice of the Meeting and this Proxy Statement are available at the &#8220;Investor
      Relations&#8221; portion of our Company&#8217;s website, <u>http://ir.sol-gel.com/</u>. The contents of that website are not a part of this Proxy Statement.&#160;</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-weight: normal; font-style: normal;" class="BRPFPageNumber">4</font></div>
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;">PROPOSAL NO. 1</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;">APPROVAL OF PRIVATE PLACEMENT TO M. ARKIN DERMATOLOGY LTD., THE </div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;">COMPANY&#8217;S CONTROLLING SHAREHOLDER</div>
    <div style="line-height: 1.25;">
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
    </div>
    <div style="line-height: 1.25;">
      <div style="text-align: justify; text-indent: 21.3pt; line-height: 1.25;">&#160; Shareholders are being requested to approve a private placement to M. Arkin Dermatology Ltd., the controlling
        shareholder of the Company (&#8220;<font style="font-weight: bold;">Arkin Dermatology</font>&#8221;). Under the Companies Law an extraordinary transaction with a controlling shareholder or in which
        a controlling shareholder has a personal interest, including a private placement in which a controlling shareholder has a personal interest, requires the approval of each of&#8201; (i) the audit committee, (ii) the board of directors and (iii) the
        shareholders, in that order. In addition, the shareholder approval must fulfill one of the following requirements:</div>
    </div>
    <div style="line-height: 1.25;">
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
    </div>
    <div style="line-height: 1.25;">
      <table cellspacing="0" cellpadding="0" id="zd04b1b54eec640518da962edff42be3d" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 18pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>approval by a majority of the votes of shareholders who do not have a personal interest in the approval of the proposal that is voted at the Meeting, excluding
                abstentions; or</div>
            </td>
          </tr>

      </table>
    </div>
    <div style="line-height: 1.25;">
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
    </div>
    <div style="line-height: 1.25;">
      <table cellspacing="0" cellpadding="0" id="zf31e2ba60ee54201b5fb2ad109f68ec9" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 18pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>the total number of shares held by shareholders who do not have a personal interest in the proposal (as described in the previous bullet-point) that is voted against
                the proposal does not exceed two percent (2%) of the aggregate voting rights in our Company.</div>
            </td>
          </tr>

      </table>
    </div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; text-indent: 20pt; line-height: 1.25;">&#160; On January 27, 2023, the Company
        entered into&#160;a securities purchase agreement&#160;(&#8220;<font style="font-weight: bold;">Investor Purchase Agreement</font>&#8221;) with Armistice Capital, pursuant to which the Company issued to Armistice Capital (i) 2,560,000 ordinary shares&#160;in a registered direct offering at a price of $5.00 per ordinary share and (ii) in a concurrent private
        placement&#160;unregistered warrants (the &#8220;<font style="font-weight: bold;">Investor&#160;Warrants</font>&#8221;) to
        purchase up to 2,560,000 ordinary shares. Each of the Investor Warrants is exercisable for one ordinary share, has an initial exercise price of $5.85 and will become exercisable beginning six months from the date&#160;of issuance&#160;and will expire on
        January 27, 2028. The gross proceeds from the offering were approximately $12.8 million.</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; text-indent: 20pt; line-height: 1.25;">&#160; Concurrently with the execution of the Investor Purchase Agreement, the Company also entered into a subscription
      agreement with Arkin Dermatology, pursuant to which Arkin Dermatology agreed to purchase 2,000,000 unregistered ordinary shares and unregistered warrants (the &#8220;<font style="font-weight: bold;">Arkin&#160;Warrants</font>&#8221;) to purchase up to 2,000,000 ordinary shares in a
      private placement (the &#8220;<font style="font-weight: bold;">Arkin Private Placement</font>&#8221;) exempt from the registration of the Securities Act of 1933, as amended (the &#8220;<font style="font-weight: bold;">Securities Act</font>&#8221;).&#160; The ordinary shares to be issued in Arkin Private Placement would be at the same price of $5.00 per ordinary share as in the
      Investor Purchase Agreement,&#160; and the Arkin Warrants would be on the same terms as the Investor Warrants. Mr. Moshe Arkin, the chairman of our board of directors, is the
        sole shareholder of Arkin Dermatology. As part of the Private Placement, the ordinary shares issued in the Arkin Private Placement and the ordinary shares
        underlying the Arkin Warrants would be registered for resale under the F-1 registration statement that is to be filed by the Company in connection with the Investor Purchase Agreement.</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; text-indent: 35.45pt; line-height: 1.25;">The Company&#8217;s audit committee and Board of Directors approved the Private Placement after determining that the
      commitment of Arkin Dermatology to invest in the Company on the same terms as Armistice Capital was important both for encouraging investment by Armistice Capital and for providing necessary capital to the Company.&#160; As result, the audit committee and<font style="font-weight: bold;">&#160;</font>the Board of Directors recommend that the shareholders vote &#8220;FOR&#8221; the proposed resolution.</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; text-indent: 21.3pt; line-height: 1.25;">&#160; &#160; &#160; <font style="font-weight: bold;">It is
        proposed that the following resolution be adopted at the Meeting:</font></div>
    <div style="text-align: justify; text-indent: 21.3pt; line-height: 1.25;">&#160;</div>
    <div style="text-align: justify; text-indent: 35.45pt; line-height: 1.25; font-style: italic; font-weight: bold;">&#160;&#8220;RESOLVED, to approve the private placement to M. Arkin Dermatology Ltd.,
      the Company&#8217;s controlling shareholder.&#8221;</div>
    <div style="text-align: justify; margin-right: 29.8pt; margin-left: 35.45pt; line-height: 1.25;">&#160;</div>
    <div style="text-align: justify; text-indent: 35.45pt; line-height: 1.25;">The affirmative vote of the holders of a majority of the voting power represented at the Meeting in person or by
      proxy and voting thereon (excluding abstentions) is required to adopt the proposed resolution.&#160; In addition, the approval of the proposal requires that either of the following two voting requirements be met:</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">&#160;</div>
    <table cellspacing="0" cellpadding="0" id="z47675ac9a2024e62bafd3b5eef77c2ed" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 0.6%; vertical-align: top;">
            <div style="text-align: justify; line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 3.86%; vertical-align: top;">
            <div style="text-align: right; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#9679;&#160;&#160;&#160;&#160; <br>
            </div>
          </td>
          <td style="width: 95.54%; vertical-align: top;">
            <div style="text-align: justify; line-height: 1.25;">approval by a majority of the votes of shareholders who do not have a personal interest in the approval of the proposal that is
              voted at the Meeting, excluding abstentions; or</div>
          </td>
        </tr>
        <tr>
          <td style="width: 0.6%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 3.86%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 95.54%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 0.6%; vertical-align: top;">
            <div style="text-align: justify; line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 3.86%; vertical-align: top;">
            <div style="text-align: right; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#9679; &#160; &#160; <br>
            </div>
          </td>
          <td style="width: 95.54%; vertical-align: top;">
            <div style="text-align: justify; line-height: 1.25;">the total number of shares held by shareholders who do not have a personal interest in the proposal (as described in the
              previous bullet-point) that is voted against the proposal does not exceed two percent (2%) of the aggregate voting rights in our Company.</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; text-indent: 35.45pt; line-height: 1.25; font-weight: bold;">The Board of Directors and audit committee recommend that the shareholders vote &#8220;FOR&#8221; the
      proposed resolution.</div>
    <div style="text-align: justify; text-indent: 35.45pt; line-height: 1.25; font-weight: bold;"> <br>
    </div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-weight: normal; font-style: normal;" class="BRPFPageNumber">5</font></div>
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: center; text-indent: 21.3pt; line-height: 1.25; font-weight: bold;">PROPOSAL NO. 2</div>
    <div style="text-align: center; text-indent: 21.3pt; line-height: 1.25;">&#160;</div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;">RENEWAL OF REGISTRATION RIGHTS AGREEMENT WITH M. ARKIN DERMATOLOGY</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="line-height: 1.25; font-weight: bold;">Background</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">On February 5, 2018, in connection with our initial public offering (the &#8220;<font style="font-weight: bold;">IPO</font>&#8221;), we entered into a registration rights agreement with Arkin Dermatology (the &#8220;<font style="font-weight: bold;">Original
        Registration Rights Agreement</font>&#8221;), pursuant to which we granted demand registration rights, short-form registration rights and piggyback registration rights to Arkin
      Dermatology.&#160; Arkin Dermatology did not exercise any of its rights under the Original Registration Rights Agreement during its term.&#160;The Original Registration Rights Agreement terminated by its own terms on the five-year anniversary of the closing of the Company&#8217;s initial public offering, on February 5, 2023.</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Arkin Dermatology was and is deemed an &#8220;affiliate&#8221; of the Company under Rule 144 of the Securities Act (&#8220;<font style="font-weight: bold;">Rule 144</font>&#8221;), as a result of which its shares were granted the registration rights under the Original Registration Rights Agreement. Without those registration rights, Arkin Dermatology is still significantly limited in its ability to resell ordinary shares.</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">In order to extend the registration
        rights to which Arkin Dermatology had been entitled until the expiration of the Original Registration Rights Agreement, each of our audit committee and Board has approved our entry into a new registration rights agreement with Arkin Dermatology
        (the &#8220;<font style="font-weight: bold;">Renewed Registration Rights Agreement</font>&#8221;).&#160; The Renewed
        Registration Rights Agreement contains substantially the same terms as the Original Registration Rights Agreement.&#160; A summary of the terms of the Renewed Registration Rights Agreement is set forth below.&#160; Shareholders are encouraged to review the
        Renewed Registration Rights Agreement, a copy of which is attached as <u>Appendix A</u> to this Proxy Statement.</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">&#160;<font style="font-style: italic;">Demand registration rights</font></div>
    <div style="line-height: 1.25;">
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
    </div>
    <div style="line-height: 1.25;">
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">At any time, subject to any &#8220;lock-up&#8221; agreement entered into with one or more underwriters (unless waived by such
        underwriters), Arkin Dermatology may request that we file a registration statement for all or&#160;a portion of the shares held by Arkin Dermatology. Upon receipt of such registration request, we would be obligated to file such a registration statement,
        so long as the aggregate gross proceeds to be received from the sale are at least $10 million, and in no event would the Company be required to effect more than two demand registration statements.</div>
    </div>
    <div style="line-height: 1.25;">
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
    </div>
    <div style="line-height: 1.25;">
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">If a demand registration involves an underwritten public offering and the managing underwriter advises us and Arkin
        Dermatology that, in its view, the number of shares&#160; requested to be included in such registration (including any securities that we propose to be included) exceeds the largest number of shares that can be sold without having an adverse effect on
        such offering, including the price at which such shares can be sold (the &#8220;Maximum Offering Size&#8221;), we shall include in such registration, in the following priority, up to the Maximum Offering Size:&#160; (i) first, all registrable securities requested
        to be included in such registration by Arkin Dermatology; and (ii) second, any securities proposed to be registered by the Company.</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">&#160;</div>
    </div>
    <div style="line-height: 1.25;">
      <div style="text-indent: 36pt; line-height: 1.25; font-style: italic;">Piggyback registration rights</div>
    </div>
    <div style="line-height: 1.25;">
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
    </div>
    <div style="text-align: justify; text-indent: 24.5pt; line-height: 1.25;">&#160;&#160;&#160; If we register any of our Company securities under the Securities Act (subject to certain exceptions, such as
      for securities issued under a share incentive plan or in connection with a merger or consolidation), Arkin Dermatology would be entitled to at least 10 business days&#8217; notice of the anticipated filing and to include all or a portion of the Company
      securities it owns of the same class or series as those to be registered by the Company in the registration. If the public offering that we are effecting is underwritten, the right of Arkin Dermatology to include shares in the registration related
      thereto is conditioned upon Arkin Dermatology accepting the terms of the underwriting as agreed between us and the underwriters. If the managing underwriter determines that the number of shares intended to be included in the registration statement
      exceeds the Maximum Offering Size, we shall include in such registration statement, in the following priority, up to the Maximum Offering Size:&#160; (i) first, so much of our securities proposed to be registered for our account as would not cause the
      offering to exceed the Maximum Offering Size, (ii) second, all registrable securities requested to be included in such registration by Arkin Dermatology, and (iii) third, any securities proposed to be registered for the account of any other persons
      with such priorities among them as we shall determine; <font style="font-style: italic;">provided</font>&#160;that, notwithstanding the foregoing, in no event shall the number of shares of
      Arkin Dermatology under the Renewed Registration Rights Agreement be reduced below 25% of the total number of securities included in such public offering.</div>
    <div style="text-align: justify; text-indent: 24.5pt; line-height: 1.25;"> <br>
    </div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-weight: normal; font-style: normal;" class="BRPFPageNumber">6</font></div>
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="line-height: 1.25;">
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-style: italic;">Shelf Registration</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">At any time, if we are eligible to use Form F-3 or Form S-3 under the Securities Act, Arkin Dermatology may request
        that we effect a registration of some or all of the shares held by Arkin Dermatology under a registration statement pursuant to Rule 415 under the Securities Act (or any successor or similar rule) (a &#8220;<font style="font-weight: bold;">Shelf Registration</font>&#8221;).&#160; We will not be obligated to effect a Shelf Registration unless the aggregate proceeds expected to be received from the sale of the shares requested to be included
        in such Shelf Registration are at least $5,000,000 (net of discounts and commissions). Arkin Dermatology may demand that we effectuate an underwritten public offering from such Shelf Registration (an &#8220;<font style="font-weight: bold;">Underwritten Takedown</font>&#8221;), provided that we shall only be required to effectuate two Underwritten Takedowns within any twelve-month period. We are currently eligible to use Form F-3.</div>
    </div>
    <div style="line-height: 1.25;">
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-indent: 36pt; line-height: 1.25; font-style: italic;">Limits on Registration Rights</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
    </div>
    <div style="line-height: 1.25;">
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">We may postpone effecting a demand registration, the filing of a Shelf Registration or effecting an Underwritten
        Takedown on two occasions during any period of twelve consecutive months for a reasonable time but not exceeding 90 days in the aggregate in any period of twelve consecutive months (which period may not be extended or renewed), if we determine that
        (i) effecting the registration would materially and adversely interfere with a significant acquisition, corporate reorganization, or other similar transaction involving us or (ii)&#160;effecting the registration would require the premature disclosure of
        material information that we have a bona fide business purpose to preserve as confidential. In addition, we have the right not to effect, or to take any action to effect, any registration statement during the period that is thirty (30) days before
        our good faith estimate of the date of filing of, and ending on a date that is ninety (90) days after the effective date of, a registration that we initiate, provided that we are actively employing in good faith commercially reasonable efforts to
        cause such registration statement to become effective.</div>
    </div>
    <div style="line-height: 1.25;">
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-indent: 36pt; line-height: 1.25; font-style: italic;">Other provisions</div>
    </div>
    <div style="line-height: 1.25;">
      <div style="line-height: 1.25;">&#160;</div>
    </div>
    <div style="line-height: 1.25;">
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">We will pay all registration expenses (other than underwriting discounts and selling commissions) and the
        reasonable fees and expenses of a single counsel for the selling shareholders, related to any demand, piggyback or shelf registration.&#160;</div>
    </div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-style: italic;">Term of agreement</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">The term of the Renewed Registration
        Rights Agreement expires upon the earlier of the five-year anniversary of the date of the agreement or, at such time as Rule 144 or another similar exemption under the Securities Act is available for the sale of all of the Company ordinary
      shares held by Arkin Dermatology without limitation during a three-month period without registration.</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Our audit committee and Board have
        expressed their view that it is in the best interests of the Company to extend the registration rights to which Arkin Dermatology was entitled until the current time by entering into the Renewed Registration Rights Agreement. Our audit
      committee and Board believe that registration of the resale of the ordinary shares held by Arkin Dermatology would facilitate the sale of such ordinary shares, which would diversify the shareholder base of the Company and increase the liquidity of
      the Company&#8217;s outstanding shares.</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-weight: normal; font-style: normal;" class="BRPFPageNumber">7</font></div>
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="line-height: 1.25;">
      <div style="text-align: justify; line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
    </div>
    <div style="text-align: justify; text-indent: 21.3pt; line-height: 1.25;">&#160;<font style="font-weight: bold;">It is proposed
        that the following resolution be adopted at the Meeting:</font></div>
    <div style="line-height: 1.25;">
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 35.45pt; line-height: 1.25;"><font style="font-weight: bold; font-style: italic;">RESOLVED, that the Company&#8217;s entry into a renewed Registration Rights Agreement with M. Arkin Dermatology, as described in Proposal 2 of the Proxy Statement with respect to the Meeting, be, and hereby is, approved in all respects</font>.</div>
    </div>
    <div style="line-height: 1.25;">
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; line-height: 1.25; font-weight: bold;">Required Vote</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
    </div>
    <div style="text-align: justify; text-indent: 35.45pt; line-height: 1.25;">The affirmative vote of the holders of a majority of the voting power represented at the Meeting in person or by
      proxy and voting thereon (excluding abstentions) is required to adopt the proposed resolution.&#160; In addition, the approval of the proposal requires that either of the following two voting requirements be met:</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">&#160;</div>
    <table cellspacing="0" cellpadding="0" id="zc8a27f0b280e467195ff2ac16a30a937" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 0.6%; vertical-align: top;">
            <div style="text-align: justify; line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 3.86%; vertical-align: top;">
            <div style="text-align: right; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#9679;&#160;&#160;&#160;&#160; <br>
            </div>
          </td>
          <td style="width: 95.54%; vertical-align: top;">
            <div style="text-align: justify; line-height: 1.25;">approval by a majority of the votes of shareholders who do not have a personal interest in the approval of the proposal that is
              voted at the Meeting, excluding abstentions; or</div>
          </td>
        </tr>
        <tr>
          <td style="width: 0.6%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 3.86%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 95.54%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 0.6%; vertical-align: top;">
            <div style="text-align: justify; line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 3.86%; vertical-align: top;">
            <div style="text-align: right; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#9679;&#160;&#160;&#160;&#160; <br>
            </div>
          </td>
          <td style="width: 95.54%; vertical-align: top;">
            <div style="text-align: justify; line-height: 1.25;">the total number of shares held by shareholders who do not have a personal interest in the proposal (as described in the
              previous bullet-point) that is voted against the proposal does not exceed two percent (2%) of the aggregate voting rights in our Company.</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; text-indent: 35.45pt; line-height: 1.25; font-weight: bold;">The Board of Directors and audit committee recommend that the shareholders vote &#8220;FOR&#8221; the
      proposed resolution.</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: center; line-height: 1.25; font-variant: small-caps; font-weight: bold;">OTHER MATTERS</div>
    <div style="text-align: justify; line-height: 1.25;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Our Board does not intend to bring any matters before the Meeting other than those specifically set forth in the
      Notice of Special Meeting of Shareholders and knows of no matters to be brought before the Meeting by others. If any other matters properly come before the Meeting, it is the intention of the persons named in the accompanying proxy to vote such proxy
      in accordance with their judgment and based on the recommendation of the Board.</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;"> <br>
    </div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-weight: normal; font-style: normal;" class="BRPFPageNumber">8</font></div>
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;">ADDITIONAL INFORMATION</div>
    <div style="text-align: justify; line-height: 1.25;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">&#160;The Company&#8217;s annual report on Form 20-F, filed with the SEC on April 4, 2022, is available for viewing and
      downloading on the SEC&#8217;s website at&#160;<u>www.sec.gov</u>&#160;as well as under the Investor Relations section of the Company&#8217;s website at&#160;<u>http://ir.sol-gel.com</u>.</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">&#160;The Company is subject to the information reporting requirements of the Securities Exchange Act of 1934 (the &#8220;<font style="font-weight: bold;">Exchange Act</font>&#8221;) applicable to foreign private issuers. The Company fulfills these requirements by filing reports with the SEC. The Company&#8217;s SEC filings
      are also available to the public on the SEC&#8217;s website at&#160;<u>www.sec.gov</u>. As a foreign private issuer, the Company is exempt from the rules under the Exchange Act
      related to the furnishing and content of proxy statements. The circulation of this Proxy Statement should not be taken as an admission that the Company is subject to those proxy rules.</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">&#160;</div>
    <div style="text-align: justify; line-height: 1.25;">Ness Ziona, Israel</div>
    <div style="text-align: justify; line-height: 1.25;">&#160;</div>
    <div style="text-align: justify; line-height: 1.25;">March 1, 2023</div>
    <div style="text-align: justify; line-height: 1.25;"> <br>
    </div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-weight: normal; font-style: normal;" class="BRPFPageNumber">9</font></div>
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: right; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-weight: bold;"><u>Appendix A</u></div>
    <div><br>
      <div style="line-height: 1.25;">
        <div style="text-align: center; line-height: 1.25; font-weight: bold;">REGISTRATION RIGHTS AGREEMENT</div>
      </div>
      <div style="line-height: 1.25;">
        <div style="line-height: 1.25">&#160;</div>
        <div style="text-indent: 24.5pt; line-height: 1.25;">AGREEMENT dated as of March [&#160;&#160; ], 2023 (this &#8220;<font style="font-weight: bold;">Agreement</font>&#8221;) among Sol-Gel Technologies Ltd., a company incorporated under the laws of the Israel (the &#8220;<font style="font-weight: bold;">Company</font>&#8221;),
          and M. Arkin Dermatology Ltd.</div>
        <div style="line-height: 1.25">&#160;</div>
        <div style="text-indent: 24.5pt; line-height: 1.25;">In consideration of the mutual promises made herein and other good and valuable consideration, the receipt and
          sufficiency of which are hereby acknowledged, the parties hereto agree as follows:</div>
      </div>
      <div style="line-height: 1.25;">
        <div style="line-height: 1.25">&#160;</div>
        <div style="text-align: center; line-height: 1.25;">ARTICLE 1</div>
      </div>
      <div style="line-height: 1.25;">
        <div style="text-align: center; line-height: 1.25;">DEFINITIONS</div>
      </div>
      <div style="line-height: 1.25;">
        <div style="line-height: 1.25">&#160;</div>
        <div style="text-indent: 24.5pt; line-height: 1.25;">Section&#160;1.01<font style="font-style: italic;">.
            Definitions.&#160;</font>(a)&#160;The following terms, as used herein, have the following meanings:</div>
      </div>
      <div style="line-height: 1.25;">
        <div style="line-height: 1.25">&#160;</div>
        <div style="text-indent: 24.5pt; line-height: 1.25;">&#8220;<font style="font-weight: bold;">Affiliate</font>&#8221;
          means, with respect to any Person, any other Person directly or indirectly controlling, controlled by or under common control with such Person,&#160;<font style="font-style: italic;">provided</font>&#160;that
          no security holder of the Company shall be deemed an Affiliate of any other security holder solely by reason of any investment in the Company. For the purpose of this definition, the term &#8220;<font style="font-weight: bold;">control</font>&#8221; (including, with correlative meanings, the terms &#8220;<font style="font-weight: bold;">controlling</font>&#8221;, &#8220;<font style="font-weight: bold;">controlled by</font>&#8221; and &#8220;<font style="font-weight: bold;">under common control with</font>&#8221;),
          as used with respect to any Person, shall mean the possession, directly or indirectly, of the power to direct or cause the direction of the management and policies of such Person, whether through the ownership of voting securities, by contract or
          otherwise.</div>
      </div>
      <div style="line-height: 1.25;">
        <div style="line-height: 1.25">&#160;</div>
        <div style="text-indent: 24.5pt; line-height: 1.25;">&#8220;<font style="font-weight: bold;">Business Day</font>&#8221;
          means any day except a Friday or a Saturday or other day on which most Israeli banking institutions are not open for business.</div>
        <div style="line-height: 1.25">&#160;</div>
        <div style="text-indent: 24.5pt; line-height: 1.25;">&#160;&#8220;<font style="font-weight: bold;">Company
            Securities</font>&#8221; means the Ordinary Shares held on the date hereof or acquired after the date hereof, including, without limitation, the Ordinary Shares and the Ordinary Shares issuable upon exercise of Warrants acquired or to be acquired by
          M. Arkin Dermatology Ltd. pursuant to that certain Subscription Agreement, dated as of January 27, 2023, between the Company and M. Arkin Dermatology Ltd.</div>
        <div style="line-height: 1.25">&#160;</div>
        <div style="text-indent: 24.5pt; line-height: 1.25;">&#8220;<font style="font-weight: bold;">Exchange Act</font>&#8221;
          means the Securities Exchange Act of 1934, as amended.</div>
        <div style="line-height: 1.25">&#160;</div>
        <div style="text-indent: 24.5pt; line-height: 1.25;">&#8220;<font style="font-weight: bold;">FINRA</font>&#8221;
          means the Financial Industry Regulatory Authority (formerly, the National Association of Securities Dealers, Inc.) and any successor thereto.</div>
      </div>
      <div style="line-height: 1.25;">
        <div style="line-height: 1.25">&#160;</div>
        <div style="text-indent: 24.5pt; line-height: 1.25;">&#8220;<font style="font-weight: bold;">Ordinary Shares</font>&#8221;
          means ordinary shares, par value NIS 0.1 per share, of the Company and any shares into which such Ordinary Shares may thereafter be converted or changed.</div>
        <div style="line-height: 1.25">&#160;</div>
        <div style="text-indent: 24.5pt; line-height: 1.25;">&#160;&#8220;<font style="font-weight: bold;">Permitted
            Transferee</font>&#8221; means in the case of any Shareholder, a Person to whom Registrable Securities or any other securities of the Company convertible or exercisable into or exchangeable for Company Securities are Transferred by such Shareholder;&#160;<font style="font-style: italic;">provided that</font>&#160;(i)&#160;such Transfer does not violate any agreements between such Shareholder and the Company or any of the Company&#8217;s subsidiaries,
          (ii)&#160;such Transfer is not made in a registered offering or pursuant to Rule 144, and (iii)&#160;such transferee is (A)&#160;an Affiliate of the Shareholder or (B)&#160;acquires at least 20% of the Shareholder&#8217;s Registrable Securities (including for these
          purposes Company Securities that are issuable upon the conversion, exercise or exchange of any other securities of the Company).</div>
        <div style="line-height: 1.25">&#160;</div>
        <div style="text-indent: 24.5pt; line-height: 1.25;">&#8220;<font style="font-weight: bold;">Person</font>&#8221;
          means an individual, corporation, limited liability company, partnership, association, trust or other entity or organization, including a government or political subdivision or an agency or instrumentality thereof.</div>
        <div style="line-height: 1.25">&#160;</div>
        <div style="text-indent: 24.5pt; line-height: 1.25;">&#8220;<font style="font-weight: bold;">Public Offering</font>&#8221;
          means an underwritten public offering of Company Securities (or any securities representing Company Securities) pursuant to an effective registration statement under the Securities Act, other than pursuant to a registration statement on Form S-4,
          Form F-4 or Form S-8 or any similar or successor form.</div>
        <div style="text-indent: 24.5pt; line-height: 1.25;"> <br>
        </div>
        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
          <div style="page-break-after: always;" class="BRPFPageBreak">
            <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
        </div>
        <!--PROfilePageNumberReset%Num%2%A - %%-->
        <div style="line-height: 1.25">&#160;</div>
        <div style="text-indent: 24.5pt; line-height: 1.25;">&#8220;<font style="font-weight: bold;">Registrable
            Securities</font>&#8221; means, at any time, any Company Securities and any other securities issued or issuable by the Company or any of its successors or assigns in respect of any such Company Securities by way of conversion, exchange, exercise,
          dividend, split, reverse split, combination, recapitalization, reclassification, merger, amalgamation, consolidation, sale of assets, other reorganization or otherwise, in each case&#160; held on the date hereof or acquired after the date hereof,
          until (i)&#160;a registration statement covering such Company Securities or such other securities has been declared effective by the SEC and such Company Securities or such other securities have been disposed of pursuant to such effective registration
          statement, (ii)&#160;such Company Securities or such other securities are sold under circumstances in which all of the applicable conditions of Rule 144 are met or (iii)&#160;all of such Company Securities and such other securities held by the holder
          thereof are eligible for sale by such holder under Rule 144 without any limitation thereunder (including with respect to volume or manner of sale) or need for current public information.</div>
      </div>
      <div style="line-height: 1.25;">
        <div style="line-height: 1.25;"><br style="line-height: 1.25;">
        </div>
        <div style="text-indent: 24.5pt; line-height: 1.25;">&#8220;<font style="font-weight: bold;">Registration
            Expenses</font>&#8221; means any and all expenses incident to the performance of, or compliance with, any registration or marketing of securities (other than transfer taxes, if any), including without limitation all (i)&#160;registration and filing fees,
          and all other fees and expenses payable in connection with the listing of securities on any securities exchange or automated interdealer quotation system, (ii)&#160;fees and expenses of compliance with any securities or &#8220;blue sky&#8221; laws (including
          reasonable fees and disbursements of counsel in connection with &#8220;blue sky&#8221; qualifications of the securities registered), (iii)&#160;expenses in connection with the preparation, printing, mailing and delivery of any registration statements,
          prospectuses and other documents in connection therewith and any amendments or supplements thereto, (iv)&#160;security engraving and printing expenses, (v)&#160;internal expenses of the Company (including all salaries and expenses of its officers and
          employees performing legal or accounting duties), (vi)&#160;reasonable fees and disbursements of counsel for the Company and customary fees and expenses for independent certified public accountants retained by the Company (including the expenses
          relating to any comfort letters or costs associated with the delivery by independent certified public accountants of any comfort letters requested pursuant to Section&#160;2.04(h)), (vii)&#160;reasonable fees and expenses of any special experts retained by
          the Company in connection with such registration, (viii)&#160; reasonable fees and disbursements of one counsel for all of the Shareholders participating in the offering selected by the Shareholders holding the majority of the Registrable Securities
          to be sold for the account of all Shareholders in the offering, in an amount not to exceed $50,000, (ix)&#160;fees and expenses in connection with any review by FINRA of the underwriting arrangements or other terms of the offering, and all fees and
          expenses of any &#8220;qualified independent underwriter,&#8221; including the fees and expenses of any counsel thereto, (x)&#160;fees and disbursements of underwriters customarily paid by issuers, but excluding any underwriting fees, discounts and commissions
          attributable to the sale of Registrable Securities, (xi)&#160;costs of printing and producing any agreements among underwriters, underwriting agreements, any &#8220;blue sky&#8221; or legal investment memoranda and any selling agreements and other documents in
          connection with the offering, sale or delivery of the Registrable Securities, (xii)&#160;transfer agents&#8217; and registrars&#8217; fees and expenses and the fees and expenses of any other agent or trustee appointed in connection with such offering,
          (xiii)&#160;expenses relating to any analyst or investor presentations or any &#8220;road shows&#8221; undertaken in connection with the registration, marketing or selling of the Registrable Securities, and (xiv)&#160;all out-of-pocket costs and expenses incurred by
          the Company or its appropriate officers in connection with their compliance with Section&#160;2.04(m). Except as set forth in clause (viii)&#160;above, Registration Expenses shall not include any out-of-pocket expenses of the Shareholders (or the agents
          who manage their accounts).</div>
      </div>
      <div style="line-height: 1.25;">
        <div style="line-height: 1.25;"><br style="line-height: 1.25;">
        </div>
        <div style="text-indent: 24.5pt; line-height: 1.25;">&#8220;<font style="font-weight: bold;">Rule 144</font>&#8221;
          means Rule 144 (or any successor or similar provisions) under the Securities Act.</div>
        <div style="line-height: 1.25">&#160;</div>
        <div style="text-indent: 24.5pt; line-height: 1.25;">&#8220;<font style="font-weight: bold;">SEC</font>&#8221; means
          the Securities and Exchange Commission.</div>
        <div style="line-height: 1.25">&#160;</div>
        <div style="text-indent: 24.5pt; line-height: 1.25;">&#8220;<font style="font-weight: bold;">Securities Act</font>&#8221;
          means the Securities Act of 1933, as amended.</div>
        <div style="line-height: 1.25">&#160;</div>
        <div style="text-indent: 24.5pt; line-height: 1.25;">&#8220;<font style="font-weight: bold;">Shareholder</font>&#8221;
          means at any time, any Person (other than the Company) who shall then be a party to or bound by this Agreement (including without limitation any Permitted Transferees who become a party to this Agreement pursuant to Section 5.01(b)), so long as
          such Person shall &#8220;beneficially own&#8221; (as such term is defined in Rule 13d-3 of the Exchange Act) any Company Securities.</div>
        <div style="text-indent: 24.5pt; line-height: 1.25;"> <br>
        </div>
        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
          <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-weight: normal; font-style: normal;" class="BRPFPageNumber">A - 2</font></div>
          <div style="page-break-after: always;" class="BRPFPageBreak">
            <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
        </div>
        <div style="line-height: 1.25">&#160;</div>
        <div style="text-indent: 24.5pt; line-height: 1.25;">&#8220;<font style="font-weight: bold;">Transfer</font>&#8221;
          means, with respect to any Company Securities or any other securities of the Company that are convertible or exercisable into or exchangeable for Company Securities, (i)&#160;when used as a verb, to sell, assign, dispose of, exchange, pledge,
          encumber, hypothecate or otherwise transfer such Company Securities or any participation or interest therein, whether directly or indirectly, or agree or commit to do any of the foregoing and (ii)&#160;when used as a noun, a direct or indirect sale,
          assignment, disposition, exchange, pledge, encumbrance, hypothecation, or other transfer of such Company Securities or any participation or interest therein or any agreement or commitment to do any of the foregoing.</div>
        <div style="line-height: 1.25">&#160;</div>
        <div style="text-indent: 24.5pt; line-height: 1.25;">Section&#160;1.02.&#160;<font style="font-style: italic;">Other
            Definitional and Interpretative Provisions.&#160;</font>The words &#8220;hereof&#8221;, &#8220;herein&#8221; and &#8220;hereunder&#8221; and words of like import used in this Agreement shall refer to this Agreement as a whole and not to any particular provision of this Agreement. The
          captions herein are included for convenience of reference only and shall be ignored in the construction or interpretation hereof. Any singular term in this Agreement shall be deemed to include the plural, and any plural term the singular.
          Whenever the words &#8220;include&#8221;, &#8220;includes&#8221; or &#8220;including&#8221; are used in this Agreement, they shall be deemed to be followed by the words &#8220;without limitation&#8221;, whether or not they are in fact followed by those words or words of like import.</div>
      </div>
      <div style="line-height: 1.25;">
        <div style="line-height: 1.25">&#160;</div>
        <div style="text-align: center; line-height: 1.25;">ARTICLE 2</div>
      </div>
      <div style="line-height: 1.25;">
        <div style="text-align: center; line-height: 1.25;">REGISTRATION&#160;RIGHTS</div>
      </div>
      <div style="line-height: 1.25;">
        <div style="line-height: 1.25">&#160;</div>
        <div style="text-indent: 24.5pt; line-height: 1.25;">Section&#160;2.01.&#160;<font style="font-style: italic;">Demand
            Registration</font>. (a)&#160; If at any time, subject to the terms of any &#8220;lock-up&#8221; agreement entered into with one or more underwriters (unless waived by such underwriter(s)), the Company shall receive a request (each such request shall be
          referred to herein as a &#8220;<font style="font-weight: bold;">Demand Registration</font>&#8221;) from a Shareholder or group of Shareholders (the requesting Shareholder(s) shall be referred to
          herein as the &#8220;<font style="font-weight: bold;">Requesting Shareholder</font>&#8221;), holding at least thirty percent (30%)&#160; of the Registrable Securities then outstanding, that the
          Company effect the registration under the Securities Act all or any portion of the Requesting Shareholder&#8217;s Registrable Securities and, in each case, specifying the intended method of disposition thereof, then the Company shall as promptly as
          practicable following the date of receipt by the Company of such request give notice of such Demand Registration&#160; at least fifteen (10)&#160;days after receipt of such Demand Registration to the other Shareholders, if any, and thereupon shall (i) as
          soon as practicable, and in any event within forty five (45) days after the date the Demand Registration is given by the Requesting Shareholder, file a registration statement under the Securities Act, and (ii) use its commercially reasonable
          efforts to effect, as expeditiously as possible, and in any event within one hundred twenty (120)&#160;days after the date the Demand Registration is given by the Requesting Shareholder, the effectiveness of the registration statement, in each case
          covering:</div>
      </div>
      <div style="line-height: 1.25;">
        <div style="line-height: 1.25;"><br style="line-height: 1.25;">
        </div>
        <div style="text-indent: 24.5pt; margin-left: 21.3pt; line-height: 1.25;">(i) subject to the restrictions set forth in Sections 2.01(e), all Registrable Securities for
          which the Requesting Shareholder has requested registration under this Section&#160;2.01, and</div>
      </div>
      <div style="line-height: 1.25;">
        <div style="line-height: 1.25">&#160;</div>
        <div style="text-indent: 24.5pt; margin-left: 21.3pt; line-height: 1.25;">(ii) subject to the restrictions set forth in Sections 2.01(e), all other Registrable
          Securities of the same class as those requested to be registered by the Requesting Shareholder that any other Shareholders (all such Shareholders, together with the Requesting Shareholder, the &#8220;<font style="font-weight: bold;">Registering Shareholders</font>&#8221;), if any, have requested the Company to register pursuant to this Section&#160;2.01, by request received by the Company within seven Business Days after such Shareholders
          receive the Company&#8217;s notice of the Demand Registration,</div>
      </div>
      <div style="line-height: 1.25;">
        <div style="line-height: 1.25;"><br style="line-height: 1.25;">
        </div>
        <div style="line-height: 1.25;">all to the extent necessary to permit the disposition (in accordance with the intended methods thereof as aforesaid) of the Registrable
          Securities so to be registered,&#160;<font style="font-style: italic;">provided</font>&#160;that, the Company shall not be obligated to effect a Demand Registration unless the aggregate
          proceeds expected to be received from the sale of the Registrable Securities requested to be included in such Demand Registration equals or exceeds $10,000,000. In no event shall the Company be required to effect more than two (2)&#160;Demand
          Registrations pursuant to this Section 2.01.</div>
      </div>
      <div style="line-height: 1.25;">
        <div style="line-height: 1.25;"><br style="line-height: 1.25;">
        </div>
        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
          <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-weight: normal; font-style: normal;" class="BRPFPageNumber">A - 3</font></div>
          <div style="page-break-after: always;" class="BRPFPageBreak">
            <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
        </div>
        <div style="line-height: 1.25">&#160;</div>
        <div style="text-indent: 24.5pt; line-height: 1.25;">(b) Promptly after the expiration of the seven-Business Day period referred to in Section&#160;2.01(a)(ii), the Company
          will notify all Registering Shareholders of the identities of the other Registering Shareholders and the number of shares of Registrable Securities requested to be included therein. At any time prior to the effective date of the registration
          statement relating to such registration, the Requesting Shareholder may revoke such request, without liability, by providing a notice to the Company revoking such request. Notwithstanding clause (d)&#160;below, a request, so revoked, shall be
          considered to be a Demand Registration unless (i)&#160;such revocation arose out of the fault of the Company (in which case the Company shall be obligated to pay all Registration Expenses in connection with such revoked request) or (ii)&#160;the Requesting
          Shareholder reimburses the Company for all Registration Expenses (other than the expenses set forth under clause (v)&#160;of the definition of the term Registration Expenses) of such revoked request.</div>
      </div>
      <div style="line-height: 1.25;">
        <div style="line-height: 1.25;">&#160;</div>
      </div>
      <div style="line-height: 1.25;">
        <div style="text-indent: 24.5pt; line-height: 1.25;">(c) The Company shall be liable for and shall pay all Registration Expenses in connection with any Demand
          Registration, regardless of whether such Registration is effected, unless the Requesting Shareholder elects to pay such Registration Expenses as described in the last sentence of Section&#160;2.01(b).</div>
      </div>
      <div style="line-height: 1.25;">
        <div style="line-height: 1.25;"><br style="line-height: 1.25;">
        </div>
        <div style="text-indent: 24.5pt; line-height: 1.25;">(d) A Demand Registration shall not be deemed to have occurred unless the registration statement relating thereto
          (i)&#160;has become effective under the Securities Act and (ii)&#160;has remained effective for a period of at least 180 days (or such shorter period in which all Registrable Securities of the Registering Shareholders included in such registration have
          actually been sold thereunder),&#160;<font style="font-style: italic;">provided</font>&#160;that a Demand Registration shall not be deemed to have occurred if, after such registration statement
          becomes effective, such registration statement is interfered with by any stop order, injunction or other order or requirement of the SEC or other governmental agency or court.</div>
        <div style="line-height: 1.25">&#160;</div>
        <div style="text-indent: 24.5pt; line-height: 1.25;">(e) If the Requesting Shareholder intends to distribute the Registrable Securities covered by their request by
          means of an underwriting, they shall so advise the Company as part of their request pursuant to section 2.01, and the Company shall include such information in their notice to the other Shareholders.&#160; If a Demand Registration involves an
          underwritten Public Offering and the managing underwriter advises the Company and the Requesting Shareholder that, in its view, the number of shares of Registrable Securities requested to be included in such registration (including any securities
          that the Company proposes to be included that are not Registrable Securities) exceeds the largest number of shares that can be sold without having an adverse effect on such offering, including the price at which such shares can be sold (the &#8220;<font style="font-weight: bold;">Maximum Offering Size</font>&#8221;), the Company shall include in such registration, in the priority listed below, up to the Maximum Offering Size:</div>
      </div>
      <div style="line-height: 1.25;">
        <div style="line-height: 1.25;"><br style="line-height: 1.25;">
        </div>
        <div style="text-indent: 24.5pt; margin-left: 21.3pt; line-height: 1.25;">(i) first, all Registrable Securities requested to be included in such registration by all
          Registering Shareholders (allocated, if necessary for the offering not to exceed the Maximum Offering Size, pro rata among such Shareholders on the basis of the relative number of Registrable Securities held by each such Shareholder, or in such
          other proportion as shall mutually be agreed to by all such Registering Shareholders); and</div>
        <div style="line-height: 1.25">&#160;</div>
        <div style="text-indent: 24.5pt; margin-left: 21.3pt; line-height: 1.25;">(ii) second, any securities proposed to be registered by the Company (including for the
          benefit of any other Persons not party to this Agreement).</div>
      </div>
      <div style="line-height: 1.25;">
        <div style="line-height: 1.25">&#160;</div>
        <div style="text-indent: 24.5pt; line-height: 1.25;">(f) The Company may postpone effecting a registration pursuant to this Section&#160;2.01 on two occasions during any
          period of twelve consecutive months for a reasonable time specified in the notice but not exceeding 90 days&#160; in the aggregate in any period of twelve consecutive months (which period may not be extended or renewed), if the Company furnishes to
          the Requesting Shareholder a certificate signed by the Company&#8217;s chief executive officer stating that (i) effecting the registration would materially and adversely interfere with a significant acquisition, corporate reorganization, or other
          similar transaction involving the Company or (ii)&#160;effecting the registration would require the premature disclosure of material information that the Company has a bona fide business purpose to preserve as confidential.&#160; In addition, the Company
          shall not be obligated to effect, or to take any action to effect, any registration pursuant to Section 2.01&#160; during the period that is thirty (30) days before the Company&#8217;s good faith estimate of the date of filing of, and ending on a date that
          is ninety (90) days after the effective date of, a Company-initiated registration (other than a registration on Form S-8 or any successor or similar forms), provided that the Company is actively employing in good faith commercially reasonable
          efforts to cause such registration statement to become effective.</div>
      </div>
      <div style="line-height: 1.25;">
        <div style="line-height: 1.25;"><br style="line-height: 1.25;">
        </div>
        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
          <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-weight: normal; font-style: normal;" class="BRPFPageNumber">A - 4</font></div>
          <div style="page-break-after: always;" class="BRPFPageBreak">
            <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
        </div>
        <div style="line-height: 1.25">&#160;</div>
        <div style="text-indent: 24.5pt; line-height: 1.25;">Section&#160;2.02.&#160;<font style="font-style: italic;">Piggyback
            Registration</font>. (a)&#160;If at any time the Company proposes to register any Company Securities under the Securities Act (other than (i)&#160;a Shelf Registration (defined below), which will be subject to the provisions of Section&#160;2.03;&#160;<font style="font-style: italic;">provided&#160;</font>that any Underwritten Takedown (defined below) will be subject to this Section&#160;2.02, or (ii)&#160;a registration on Form S-8, F-4 or S-4, or
          any successor or similar forms, relating to Ordinary Shares issuable upon exercise of employee stock options or in connection with any employee benefit or similar plan of the Company or in connection with a direct or indirect acquisition by the
          Company of another Person), whether or not for sale for its own account, the Company shall each such time give prompt notice at least ten (10)&#160;Business Days prior to the anticipated filing date of the registration statement relating to such
          registration to each Shareholder, which notice shall set forth such Shareholder&#8217;s rights under this Section&#160;2.02 and shall offer such Shareholder the opportunity to include in such registration statement the number of Registrable Securities of
          the same class or series as those proposed to be registered as each&#160; Shareholder may request (a &#8220;<font style="font-weight: bold;">Piggyback Registration</font>&#8221;), subject to the
          provisions of Section&#160;2.02(b). Upon the request of any such Shareholder made within five (5)&#160;Business Days after the receipt of notice from the Company (which request shall specify the number of Registrable Securities intended to be registered by
          such Shareholder), the Company shall use all commercially reasonable efforts to effect the registration under the Securities Act of all Registrable Securities that the Company has been so requested to register by all such Shareholders, to the
          extent required to permit the disposition of the Registrable Securities so to be registered,&#160;<font style="font-style: italic;">provided</font>&#160;that (A)&#160;if such registration involves
          an underwritten Public Offering, all such Shareholders requesting to be included in the Company&#8217;s registration must sell their Registrable Securities to the underwriters selected as provided in Section&#160;2.04(f) on the same terms and conditions as
          apply to the Company, and (B)&#160;if, at any time after giving notice of its intention to register any Company Securities pursuant to this Section&#160;2.02(a) and prior to the effective date of the registration statement filed in connection with such
          registration, the Company shall determine for any reason not to register such securities, the Company shall give notice to all such Shareholders and, thereupon, shall be relieved of its obligation to register any Registrable Securities in
          connection with such registration. No registration effected under this Section&#160;2.02 shall relieve the Company of its obligations to effect a Demand Registration to the extent required by Section&#160;2.01 or a Shelf Registration to the extent required
          by Section&#160;2.03. The Company shall pay all Registration Expenses in connection with each Piggyback Registration.</div>
      </div>
      <div style="line-height: 1.25;">
        <div style="line-height: 1.25;">&#160;</div>
      </div>
      <div style="line-height: 1.25;">
        <div style="text-indent: 24.5pt; line-height: 1.25;">(b) If a Piggyback Registration involves an underwritten Public Offering and the managing underwriter advises the
          Company that, in its view, the number of Shares that the Company and the Shareholders intend to include in such registration exceeds the Maximum Offering Size, the Company shall include in such registration, in the following priority, up to the
          Maximum Offering Size:</div>
      </div>
      <div style="line-height: 1.25;">
        <div style="line-height: 1.25;"><br style="line-height: 1.25;">
        </div>
        <div style="text-indent: 24.5pt; margin-left: 21.3pt; line-height: 1.25;">(i) first, so much of the Company Securities proposed to be registered for the account of the
          Company (or, if such registration is pursuant to a demand by a Person that is not a Shareholder, for the account of such other Person) as would not cause the offering to exceed the Maximum Offering Size,</div>
        <div style="line-height: 1.25">&#160;</div>
        <div style="text-indent: 24.5pt; margin-left: 21.3pt; line-height: 1.25;">(ii) second, all Registrable Securities requested to be included in such registration by any
          Shareholders pursuant to this Section&#160;2.02 (allocated, if necessary for the offering not to exceed the Maximum Offering Size, pro rata among such Shareholders on the basis of the relative number of Registrable Securities held by each such
          Shareholder, or in such other proportion as shall mutually be agreed to by all such Registering Shareholders), and</div>
        <div style="line-height: 1.25">&#160;</div>
        <div style="text-indent: 24.5pt; margin-left: 21.3pt; line-height: 1.25;">(iii) third, any securities proposed to be registered for the account of any other Persons
          with such priorities among them as the Company shall determine;</div>
      </div>
      <div style="line-height: 1.25;">
        <div style="line-height: 1.25">&#160;</div>
        <div style="line-height: 1.25;"><font style="font-style: italic;">provided</font>&#160;that, notwithstanding
          the foregoing, in no event shall the number of Registrable Securities included in the underwritten Public Offering be reduced below 25% of the total number of securities included in such Public Offering.</div>
      </div>
      <div style="line-height: 1.25;">
        <div style="line-height: 1.25;"><br style="line-height: 1.25;">
        </div>
        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
          <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-weight: normal; font-style: normal;" class="BRPFPageNumber">A - 5</font></div>
          <div style="page-break-after: always;" class="BRPFPageBreak">
            <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
        </div>
        <div style="line-height: 1.25">&#160;</div>
        <div style="text-indent: 24.5pt; line-height: 1.25;">Section&#160;2.03.&#160;<font style="font-style: italic;">Shelf
            Registration</font>. (a)&#160;At any time, if the Company is eligible to use Form F-3 or Form S-3, a Shareholder or group of Shareholders (referred to herein as the &#8220;<font style="font-weight: bold;">Shelf Requesting Shareholder</font>&#8221;) may request the Company to effect a registration of some or all of the Registrable Securities held by such Shelf Requesting Shareholder under a Registration Statement pursuant to Rule
          415 under the Securities Act (or any successor or similar rule) (a &#8220;<font style="font-weight: bold;">Shelf Registration</font>&#8221;);<font style="font-style: italic;">&#160;provided</font>&#160;that, the Company shall not be obligated to effect a Shelf Registration unless the aggregate proceeds expected to be received from the sale of the Registrable Securities requested to
          be included in such Shelf Registration equals or exceeds $5,000,000 (net of discounts and commissions). A Shareholder or group of Shareholders whose Registrable Securities are included in such Shelf Registration or may be included therein without
          the need for an amendment to such Shelf Registration (other than an automatically effective amendment) may demand that the Company to effectuate a Public Offering from such Shelf Registration (an &#8220;<font style="font-weight: bold;">Underwritten Takedown</font>&#8221;), provided that the Company shall only be required to effectuate two Underwritten Takedowns within any twelve-month period. The provisions of Section&#160;2.01 shall apply&#160;<font style="font-style: italic;">mutatis mutandis</font>&#160;to each Underwritten Takedown, with references to &#8220;filing of the registration statement&#8221; or &#8220;effective date&#8221; being deemed
          references to filing of a prospectus or supplement for such offering and references to &#8220;registration&#8221; being deemed references to the offering;&#160;<font style="font-style: italic;">provided</font>&#160;that
          Registering Shareholders shall only include Shareholders whose Registrable Securities are included in such Shelf Registration or may be included therein without the need for an amendment to such Shelf Registration (other than an automatically
          effective amendment). So long as the Shelf Registration is effective, no Shareholder may request any Demand Registration pursuant to Section&#160;2.01 with respect to Registrable Shares that are registered on such Shelf Registration but instead shall
          have the right to request an Underwritten Takedown as set forth above.</div>
        <div style="line-height: 1.25">&#160;</div>
        <div style="text-indent: 24.5pt; line-height: 1.25;">(b) If the Company shall receive a request from a Shelf Requesting Shareholder that the Company effect a Shelf
          Registration, then the Company shall as promptly as practicable following the date of receipt by the Company of such request give notice of such requested registration and at least ten (10)&#160;Business Days prior to the anticipated filing date of
          the registration statement relating to such Shelf Registration to the other Shareholders and thereupon shall (i) as soon as practicable, and in any event within forty five (45) days after the date the request for a Shelf Registration is given by
          the Shelf Requesting Shareholder, file a registration statement on Form F-3 or S-3, as applicable, under the Securities Act, and (ii) use its reasonable best efforts to effect, as expeditiously as possible, and in any event within one hundred
          (120)&#160;days after the date the request for a Shelf Registration is given by the Shelf Requesting Shareholder, the effectiveness of a registration statement under the Securities Act, in each case covering:</div>
        <div style="line-height: 1.25">&#160;</div>
        <div style="text-indent: 24.5pt; line-height: 1.25;">(i) all Registrable Securities for which the Shelf Requesting Shareholder has requested registration under this
          Section&#160;2.03, and</div>
        <div style="line-height: 1.25">&#160;</div>
        <div style="text-indent: 24.5pt; line-height: 1.25;">(ii) all other Registrable Securities of the same class as those requested to be registered by the Shelf
          Requesting Shareholder that any other Shareholders (all such Shareholders, together with the Shelf Requesting Shareholder, the &#8220;<font style="font-weight: bold;">Shelf Registering
            Shareholders</font>&#8221;) have requested the Company to register by request received by the Company within five (5)&#160;Business Days after such Shareholders receive the Company&#8217;s notice of the Shelf Registration, all to the extent necessary to permit
          the registration of the Registrable Securities so to be registered on such Shelf Registration.</div>
        <div style="line-height: 1.25">&#160;</div>
        <div style="text-indent: 24.5pt; line-height: 1.25;">(c) At any time prior to the effective date of the registration statement relating to such Shelf Registration, the
          Shelf Requesting Shareholder may revoke such request, without liability, by providing a notice to the Company revoking such request.</div>
      </div>
      <div style="line-height: 1.25;">
        <div style="line-height: 1.25">&#160;</div>
        <div style="text-indent: 24.5pt; line-height: 1.25;">(d) The Company shall be liable for and pay all Registration Expenses in connection with any Shelf Registration.</div>
        <div style="line-height: 1.25">&#160;</div>
        <div style="text-indent: 24.5pt; line-height: 1.25;">(e) The Company may postpone effecting a registration or an Underwritten Takedown pursuant to this Section&#160;2.03 on
          two occasions during any period of twelve consecutive months for a reasonable time specified in the notice but not exceeding 90 days in the aggregate in any period of twelve consecutive months (which period may not be extended or renewed), if the
          Company furnishes to Requesting Shareholder a certificate signed by the Company&#8217;s chief executive officer stating that (i) effecting the registration would materially and adversely interfere with a significant acquisition, corporate
          reorganization, or other similar transaction involving the Company or (ii)&#160;effecting the registration would require the premature disclosure of material information that the Company has a bona fide business purpose to preserve as confidential.&#160;
          In addition, the Company shall not be obligated to effect, or to take any action to effect, any registration or any Underwritten Takedown pursuant to Section 2.03&#160; during the period that is thirty (30) days before the Company&#8217;s good faith
          estimate of the date of filing of, and ending on a date that is ninety (90) days after the effective date of, a Company-initiated registration (other than a registration on Form S-8 or any successor or similar forms), provided that the Company is
          actively employing in good faith commercially reasonable efforts to cause such registration statement to become effective.</div>
      </div>
      <div style="line-height: 1.25;">
        <div style="line-height: 1.25;"><br style="line-height: 1.25;">
        </div>
        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
          <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-weight: normal; font-style: normal;" class="BRPFPageNumber">A - 6</font></div>
          <div style="page-break-after: always;" class="BRPFPageBreak">
            <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
        </div>
        <div style="line-height: 1.25">&#160;</div>
        <div style="text-indent: 24.5pt; line-height: 1.25;">Section&#160;2.04.&#160;<font style="font-style: italic;">Registration
            Procedures</font>. In connection with Section&#160;2.01, 2.02 and 2.03, subject to the provisions of such Sections, the Company shall use all commercially reasonable efforts to effect the registration and the sale of such Registrable Securities in
          accordance with the intended method of disposition thereof as quickly as practicable, and, in connection with any such request:</div>
      </div>
      <div style="line-height: 1.25;">
        <div style="line-height: 1.25;"><br style="line-height: 1.25;">
        </div>
        <div style="text-indent: 24.5pt; line-height: 1.25;">(a) The Company shall as expeditiously as possible prepare and file with the SEC a registration statement on any
          form for which the Company then qualifies or that counsel for the Company shall deem appropriate and which form shall be available for the sale of the Registrable Securities to be registered thereunder in accordance with the intended method of
          distribution thereof, and use all commercially reasonable efforts to cause such filed registration statement to become and remain effective for a period of not less than 180 days or in the case of a Shelf Registration, three years (or such
          shorter period in which all of the Registrable Securities of the Shareholders included in such registration statement shall have actually been sold thereunder or cease to be Registrable Securities). Any such registration statement shall be an
          automatically effective registration statement to the extent permitted by the SEC&#8217;s rules and regulations.</div>
        <div style="line-height: 1.25">&#160;</div>
        <div style="text-indent: 24.5pt; line-height: 1.25;">(b) Prior to filing a registration statement or prospectus or any amendment or supplement thereto (other than any
          report filed pursuant to the Exchange Act that is incorporated by reference therein), the Company shall, if requested, furnish to each participating Shareholder and each underwriter, if any, of the Registrable Securities covered by such
          registration statement copies of such registration statement as proposed to be filed, and thereafter the Company shall furnish to such Shareholder and underwriter, if any, such number of copies of such registration statement, each amendment and
          supplement thereto (in each case including all exhibits thereto and documents incorporated by reference therein), the prospectus included in such registration statement (including each preliminary prospectus and any summary prospectus) and any
          other prospectus filed under Rule 424, Rule 430A, Rule 430B or Rule 430C under the Securities Act and such other documents as such Shareholder or underwriter may reasonably request in order to facilitate the disposition of the Registrable
          Securities owned by such Shareholder.</div>
      </div>
      <div style="line-height: 1.25;">
        <div style="line-height: 1.25;">&#160;</div>
      </div>
      <div style="line-height: 1.25;">
        <div style="text-indent: 24.5pt; line-height: 1.25;">(c) After the filing of the registration statement, the Company shall (i)&#160;cause the related prospectus to be
          supplemented by any required prospectus supplement and, as so supplemented, to be filed pursuant to Rule 424 under the Securities Act, (ii)&#160;comply with the provisions of the Securities Act with respect to the disposition of all Registrable
          Securities covered by such registration statement during the applicable period in accordance with the intended methods of disposition by the Shareholders thereof set forth in such registration statement or supplement to such prospectus and
          (iii)&#160;promptly notify each Shareholder holding Registrable Securities covered by such registration statement of any stop order issued or threatened by the SEC or any state securities commission and take all reasonable actions required to prevent
          the entry of such stop order or to remove it if entered.</div>
      </div>
      <div style="line-height: 1.25;">
        <div style="line-height: 1.25">&#160;</div>
        <div style="text-indent: 24.5pt; line-height: 1.25;">(d) The Company shall use all commercially reasonable efforts to (i)&#160;register or qualify the Registrable
          Securities covered by such registration statement under such other securities or &#8220;blue sky&#8221; laws of such jurisdictions in the United States as any Registering Shareholder or Shelf Registering Shareholder holding such Registrable Securities
          reasonably (in light of such Shareholder&#8217;s intended plan of distribution) requests and (ii)&#160;cause such Registrable Securities to be registered with or approved by such other governmental agencies or authorities as may be necessary by virtue of
          the business and operations of the Company and do any and all other acts and things that may be reasonably necessary or advisable to enable such Shareholder to consummate the disposition of the Registrable Securities owned by such Shareholder,&#160;<font style="font-style: italic;">provided</font>&#160;that the Company shall not be required to (A)&#160;qualify generally to do business in any jurisdiction where it would not otherwise be
          required to qualify but for this Section&#160;2.04(d), (B)&#160;subject itself to taxation in any such jurisdiction or (C)&#160;consent to general service of process in any such jurisdiction.</div>
        <div style="line-height: 1.25">&#160;</div>
        <div style="text-indent: 24.5pt; line-height: 1.25;">(e) The Company shall promptly notify each Shareholder holding such Registrable Securities covered by such
          registration statement, at any time when a prospectus relating thereto is required to be delivered under the Securities Act, of the occurrence of an event requiring the preparation of a supplement or amendment to such prospectus so that, as
          thereafter delivered to the purchasers of such Registrable Securities, such prospectus will not contain an untrue statement of a material fact or omit to state any material fact required to be stated therein or necessary in order to make the
          statements therein in the light of the circumstances under which they were made at such time not misleading and promptly prepare and make available to each such Shareholder and file with the SEC any such supplement or amendment.</div>
        <div style="text-indent: 24.5pt; line-height: 1.25;"> <br>
        </div>
        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
          <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-weight: normal; font-style: normal;" class="BRPFPageNumber">A - 7</font></div>
          <div style="page-break-after: always;" class="BRPFPageBreak">
            <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
        </div>
      </div>
      <div style="line-height: 1.25;">
        <div style="line-height: 1.25;">&#160;</div>
      </div>
      <div style="line-height: 1.25;">
        <div style="text-indent: 24.5pt; line-height: 1.25;">(f) The Company shall have the right to select an underwriter or underwriters in connection with any Public
          Offering resulting from any exercise of a Demand Registration (including any Underwritten Takedown), which underwriter or underwriters shall be reasonably acceptable to the Requesting Shareholder. In connection with any Public Offering, the
          Company shall enter into customary agreements (including an underwriting agreement in customary form) and take such all other actions as are reasonably required in order to expedite or facilitate the disposition of such Registrable Securities in
          any such Public Offering, including the engagement of a &#8220;qualified independent underwriter&#8221; in connection with the qualification of the underwriting arrangements with FINRA.</div>
      </div>
      <div style="line-height: 1.25;">
        <div style="line-height: 1.25;"><br style="line-height: 1.25;">
        </div>
        <div style="text-indent: 24.5pt; line-height: 1.25;">(g) Upon execution of confidentiality agreements in form and substance reasonably satisfactory to the Company, the
          Company shall, in connection with a Public Offering make available for inspection by any Shareholder and any underwriter participating in any disposition pursuant to a registration statement being filed by the Company pursuant to this Agreement
          and any attorney, accountant or other professional retained by any such Shareholder or underwriter (collectively, the &#8220;<font style="font-weight: bold;">Inspectors</font>&#8221;), all
          financial and other records, pertinent corporate documents and properties of the Company (collectively, the &#8220;<font style="font-weight: bold;">Records</font>&#8221;) as shall be reasonably
          necessary or desirable to enable any of the Inspectors to exercise its due diligence responsibility, and cause the Company&#8217;s officers, directors and employees to supply all information reasonably requested by any Inspectors in connection with
          such registration statement. Records that the Company determines, in good faith, to be confidential and that it notifies the Inspectors are confidential shall not be disclosed by the Inspectors unless (i)&#160;the disclosure of such Records is
          necessary to avoid or correct a material misstatement or omission in such registration statement or (ii)&#160;the release of such Records is ordered pursuant to a subpoena or other order from a court of competent jurisdiction. Each Shareholder agrees
          that information obtained by it as a result of such inspections shall be deemed confidential and shall not be used by it or its Affiliates as the basis for any market transactions in the Company Securities unless and until such information is
          made generally available to the public. Each Shareholder further agrees that, upon learning that disclosure of such Records is sought in a court of competent jurisdiction, it shall give notice to the Company and allow the Company, at its expense,
          to undertake appropriate action to prevent disclosure of the Records deemed confidential.</div>
        <div style="line-height: 1.25">&#160;</div>
        <div style="text-indent: 24.5pt; line-height: 1.25;">(h) In connection with any Public Offering, the Company shall use its reasonable best efforts to furnish to each
          underwriter, if any, a signed counterpart, addressed to such underwriter, of (i)&#160;an opinion or opinions of counsel to the Company and (ii)&#160;a comfort letter or comfort letters from the Company&#8217;s independent public accountants, each in customary
          form and covering such matters of the kind customarily covered by opinions or comfort letters, as the case may be, as the managing underwriter therefor reasonably requests.</div>
      </div>
      <div style="line-height: 1.25;">
        <div style="line-height: 1.25;">&#160;</div>
      </div>
      <div style="line-height: 1.25;">
        <div style="text-indent: 24.5pt; line-height: 1.25;">(i) The Company shall otherwise use its reasonable best efforts to comply with all applicable rules and
          regulations of the SEC, and make available to its security holders, as soon as reasonably practicable, an earnings statement or such other document covering a period of twelve months, beginning within three months after the effective date of the
          registration statement, which earnings statement satisfies the requirements of Rule 158 under the Securities Act.</div>
      </div>
      <div style="line-height: 1.25;">
        <div style="line-height: 1.25">&#160;</div>
        <div style="text-indent: 24.5pt; line-height: 1.25;">(j) The Company may require each Shareholder promptly to furnish in writing to the Company such information
          regarding the distribution of the Registrable Securities as the Company may from time to time reasonably request and such other information as may be legally required in connection with such registration. In connection with a Shelf Registration,
          any Shareholder that does not provide such information within five (5)&#160;Business Days of a request by the Company (which request is made before filing of the Shelf Registration) may have its Registrable Securities excluded from such Shelf
          Registration;&#160;<font style="font-style: italic;">provided</font>&#160;that such securities shall be added within fifteen Business Days after the Shareholder provides such information if the
          Company may add such securities to such Shelf Registration without the need for a post-effective amendment (other than an automatically effective amendment) to the Shelf Registration.</div>
        <div style="text-indent: 24.5pt; line-height: 1.25;"> <br>
        </div>
        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
          <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-weight: normal; font-style: normal;" class="BRPFPageNumber">A - 8</font></div>
          <div style="page-break-after: always;" class="BRPFPageBreak">
            <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
        </div>
        <div style="line-height: 1.25">&#160;</div>
        <div style="text-indent: 24.5pt; line-height: 1.25;">(k) Each Shareholder agrees that, upon receipt of any notice from the Company of the happening of any event of the
          kind described in Section&#160;2.04(e), such Shareholder shall forthwith discontinue disposition of Registrable Securities pursuant to the registration statement covering such Registrable Securities until such Shareholder&#8217;s receipt of the copies of
          the supplemented or amended prospectus contemplated by Section&#160;2.04(e), and, if so directed by the Company, such Shareholder shall deliver to the Company all copies, other than any permanent file copies then in such Shareholder&#8217;s possession, of
          the most recent prospectus covering such Registrable Securities at the time of receipt of such notice. If the Company shall give such notice, the Company shall extend the period during which such registration statement shall be maintained
          effective (including the period referred to in Section&#160;2.04(a)) by the number of days during the period from and including the date of the giving of notice pursuant to Section&#160;2.04(e) to the date when the Company shall make available to such
          Shareholder a prospectus supplemented or amended to conform with the requirements of Section&#160;2.04(e).</div>
        <div style="line-height: 1.25">&#160;</div>
        <div style="text-indent: 24.5pt; line-height: 1.25;">(l) The Company shall use its reasonable best efforts to list all Registrable Securities covered by such
          registration statement on any securities exchange or quotation system on which the Ordinary Shares are then listed or traded.</div>
        <div style="line-height: 1.25">&#160;</div>
        <div style="text-indent: 24.5pt; line-height: 1.25;">(m) In any Public Offering pursuant to a Demand Registration, the Company shall have appropriate officers of the
          Company (i)&#160;prepare and make presentations at any &#8220;road shows&#8221; and before analysts and (ii)&#160;otherwise use their reasonable best efforts to cooperate as reasonably requested by the underwriters in the offering, marketing or selling of the
          Registrable Securities.</div>
      </div>
      <div style="line-height: 1.25;">
        <div style="line-height: 1.25;">&#160;</div>
      </div>
      <div style="line-height: 1.25;">
        <div style="text-indent: 24.5pt; line-height: 1.25;">(n) Each Shareholder agrees that, in connection with any offering pursuant to this Agreement, it will not prepare
          or use or refer to, any &#8220;free writing prospectus&#8221; (as defined in Rule 405 of the Securities Act) without the prior written authorization of the Company (which authorization shall not be unreasonably withheld), and will not distribute any written
          materials in connection with the offer or sale of the Registrable Securities pursuant to any registration statement hereunder other than the prospectus and any such free writing prospectus so authorized.</div>
      </div>
      <div style="line-height: 1.25;">
        <div style="line-height: 1.25">&#160;</div>
        <div style="text-indent: 24.5pt; line-height: 1.25;">Section&#160;2.05<font style="font-style: italic;">.
            Participation In Public Offering.&#160;</font>No Shareholder may participate in any Public Offering hereunder unless such Shareholder (a)&#160;agrees to sell such Shareholder&#8217;s Registrable Securities on the basis provided in any underwriting arrangements
          approved by the Persons entitled hereunder to approve such arrangements and (b)&#160;completes and executes all questionnaires, powers of attorney, indemnities, underwriting agreements, &#8220;lock-up&#8221; agreements and other documents reasonably required
          under the terms of such underwriting arrangements that are in customary form and consistent with the provisions of this Agreement in respect of registration rights.</div>
        <div style="line-height: 1.25">&#160;</div>
        <div style="text-indent: 24.5pt; line-height: 1.25;">Section&#160;2.06<font style="font-style: italic;">.
            Rule 144 Sales; Cooperation By The Company.&#160;</font>If any Shareholder shall transfer any Registrable Securities pursuant to Rule 144, the Company shall cooperate, to the extent commercially reasonable, with such Shareholder and shall provide to
          such Shareholder such information as such Shareholder shall reasonably request. Without limiting the foregoing, the Company shall at any time after any of the Company&#8217;s Ordinary Shares are registered under the Securities Act or the Exchange Act,
          use commercially reasonable efforts to: (i)&#160;make and keep available public information, as those terms are contemplated by Rule 144; (ii)&#160;timely file with the SEC all reports and other documents required to be filed under the Securities Act and
          the Exchange Act; and (iii)&#160;furnish to each Shareholder forthwith upon request a written statement by the Company as to its compliance with the reporting requirements of the Securities Act and the Exchange Act, a copy of the most recent annual or
          quarterly report of the Company, and such other information as such Shareholder may reasonably request in order to avail itself of any rule or regulation of the SEC allowing such Shareholder to sell any Registrable Securities without
          registration.</div>
        <div style="text-indent: 24.5pt; line-height: 1.25;"> <br>
        </div>
        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
          <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-weight: normal; font-style: normal;" class="BRPFPageNumber">A - 9</font></div>
          <div style="page-break-after: always;" class="BRPFPageBreak">
            <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
        </div>
      </div>
      <div style="line-height: 1.25;">
        <div style="line-height: 1.25;"><br style="line-height: 1.25;">
        </div>
        <div style="text-align: center; line-height: 1.25;">ARTICLE 3</div>
      </div>
      <div style="line-height: 1.25;">
        <div style="text-align: center; line-height: 1.25;">INDEMNIFICATION&#160;AND&#160;CONTRIBUTION</div>
      </div>
      <div style="line-height: 1.25;">
        <div style="line-height: 1.25">&#160;</div>
        <div style="text-indent: 24.5pt; line-height: 1.25;">Section&#160;3.01.&#160;<font style="font-style: italic;">Indemnification by the Company</font>. To the extent permitted by law, the
            Company will indemnify and hold harmless each Shareholder beneficially owning any Registrable Securities covered by a registration statement, its officers, directors, employees, partners, members. agents, legal counsel and accountants, and any
            underwriter (as defined under the Securities Act) for such Shareholder and its officers and directors, and each Person, if any, who controls such Shareholder or underwriter within the meaning of Section&#160;15 of the Securities Act or Section&#160;20 of
            the Exchange Act from and against any and all losses, claims, damages, liabilities and expenses (including reasonable expenses of investigation and reasonable attorneys&#8217; fees and expenses) (collectively, &#8220;<font style="font-weight: bold;">Damages</font>&#8221;) and the Company will pay to each such Holder, underwriter, controlling Person, or
            other aforementioned Person any legal or other expenses reasonably incurred thereby in connection with investigating or defending any claim or proceeding from
            which Damages may result, as such expenses are incurred, caused by or relating to any untrue statement or alleged untrue statement of a material fact contained in any registration statement or prospectus relating to the Registrable Securities
            (as amended or supplemented if the Company shall have furnished any amendments or supplements thereto) or any preliminary prospectus or free-writing prospectus (as defined in Rule 405 under the Securities Act), or caused by or relating to any
            omission or alleged omission to state therein a material fact required to be stated therein or necessary to make the statements therein not misleading, or any violation or alleged violation by the indemnifying<font style="font-weight: bold;">&#160;</font>party (or any of its agents or Affiliates)<font style="font-weight: bold;">&#160;</font>of the Securities Act, the Exchange Act, any state securities law, or any rule or regulation
            promulgated under the Securities Act, the Exchange Act, or any state securities law, except insofar as such Damages are caused by or related to any such untrue statement or omission or alleged untrue statement or omission so made in reliance
            upon and in conformity with information furnished in writing to the Company by or on behalf of such Shareholder, underwriter, controlling Person or other aforementioned Person expressly for use therein.</div>
        <div style="line-height: 1.25">&#160;</div>
        <div style="text-indent: 24.5pt; line-height: 1.25;">Section&#160;3.02.&#160;<font style="font-style: italic;">Indemnification
            by Participating Shareholders</font>. To the extent permitted by law, each Shareholder holding Registrable Securities included in any registration statement agrees, severally but not jointly, will indemnify and hold harmless the Company, its
          officers, directors, agents, legal counsel and accountants, any underwriter (as defined in the Securities Act) and its officers and directors, any other Shareholder selling securities in such registration statement, and each Person, if any, who
          controls the Company, such underwriter or other Shareholder within the meaning of Section&#160;15 of the Securities Act or Section&#160;20 of the Exchange Act to the same extent as the indemnity from the Company to such Shareholder provided in
          Section&#160;3.01, but only to the extent such Damages arise out of or are based upon actions and omissions made in reliance upon and in conformity with information about such Shareholder furnished in writing by or on behalf of such Shareholder
          expressly for use in any registration statement or prospectus relating to the Registrable Securities, or any amendment or supplement thereto, or any preliminary prospectus or free-writing prospectus. No Shareholder shall be liable under this
          Section&#160;3.02 for any Damages in excess of the net proceeds realized by such Shareholder in the sale of Registrable Securities of such Shareholder to which such Damages relate, except in the case of fraud or willful misconduct by such Shareholder.</div>
      </div>
      <div style="line-height: 1.25;">
        <div style="line-height: 1.25;">&#160;</div>
      </div>
      <div style="line-height: 1.25;">
        <div style="text-indent: 24.5pt; line-height: 1.25;">Section&#160;3.03.&#160;<font style="font-style: italic;">Conduct
            of Indemnification Proceedings</font>. If any proceeding (including any governmental investigation) shall be brought or asserted against any Person in respect of which indemnity may be sought pursuant to this Article 3, such Person (an &#8220;<font style="font-weight: bold;">Indemnified Party</font>&#8221;) shall promptly notify the Person against whom such indemnity may be sought (the &#8220;<font style="font-weight: bold;">Indemnifying Party</font>&#8221;) in writing and the Indemnifying Party shall assume the defense thereof, including the employment of counsel satisfactory to such Indemnified Party, and shall
          assume the payment of all fees and expenses,&#160;<font style="font-style: italic;">provided</font>&#160;that the failure of any Indemnified Party so to notify the Indemnifying Party shall not
          relieve the Indemnifying Party of its obligations hereunder except to the extent that the Indemnifying Party is materially prejudiced by such failure to notify. In any such proceeding, any Indemnified Party shall have the right to retain its own
          counsel, but the fees and expenses of such counsel shall be at the expense of such Indemnified Party unless (a)&#160;the Indemnifying Party and the Indemnified Party shall have mutually agreed to the retention of such counsel, (b)&#160;in the reasonable
          judgment of such Indemnified Party representation of both parties by the same counsel would be inappropriate due to actual or potential differing interests between them, including one or more defenses or counterclaims that are different from or
          in addition to those available to the Indemnifying Party, or (c)&#160;the Indemnifying Party shall have failed to assume the defense within 30 days of notice pursuant to this Section&#160;3.03. It is understood that, in connection with any proceeding or
          related proceedings in the same jurisdiction, the Indemnifying Party shall not be liable for the reasonable fees and expenses of more than one separate firm of attorneys (in addition to one local counsel per jurisdiction) at any time for all such
          Indemnified Parties, and that all such fees and expenses shall be reimbursed as they are incurred. In the case of any such separate firm for the Indemnified Parties, such firm shall be designated in writing by the Indemnified Parties. The
          Indemnifying Party shall not be liable for any settlement of any proceeding effected without its written consent, but if settled with such consent, or if there be a final judgment for the plaintiff, the Indemnifying Party shall indemnify and hold
          harmless such Indemnified Parties from and against any loss or liability (to the extent stated above) by reason of such settlement or judgment. Without the prior written consent of the Indemnified Party, no Indemnifying Party shall effect any
          settlement of any pending or threatened proceeding in respect of which any Indemnified Party is or could have been a party and indemnity could have been sought hereunder by such Indemnified Party, unless such settlement (A)&#160;includes an
          unconditional release of such Indemnified Party from all liability arising out of such proceeding, and (B)&#160;does not include any injunctive or other equitable or non-monetary relief applicable to or affecting such Indemnified Person.</div>
        <div style="text-indent: 24.5pt; line-height: 1.25;"> <br>
        </div>
        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
          <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-weight: normal; font-style: normal;" class="BRPFPageNumber">A - 10</font></div>
          <div style="page-break-after: always;" class="BRPFPageBreak">
            <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
        </div>
      </div>
      <div style="line-height: 1.25;">
        <div style="line-height: 1.25;"><br style="line-height: 1.25;">
        </div>
        <div style="text-indent: 24.5pt; line-height: 1.25;">Section&#160;3.04.&#160;<font style="font-style: italic;">Contribution</font>.
          If the indemnification provided for in this Article 3 is unavailable to or unenforceable by the Indemnified Parties in respect of any Damages, then each Indemnifying Party, in lieu of indemnifying the Indemnified Parties, shall contribute to the
          amount paid or payable by such Indemnified Party, in such proportion as is appropriate to reflect the relative fault of the Indemnifying Party and Indemnified Party in connection with the actions, statements or omissions that resulted in such
          Damages as well as any other relevant equitable considerations. The relative fault of such Indemnifying Party and Indemnified Party shall be determined by reference to, among other things, whether any action in question, including any untrue or
          alleged untrue statement of a material fact or omission or alleged omission of a material fact, has been taken or made by, or relates to information supplied by, such Indemnifying Party or Indemnified Party, and the parties&#8217; relative intent,
          knowledge, access to information and opportunity to correct or prevent such action, statement or omission. The amount paid or payable by a party as a result of any Damages shall be deemed to include, subject to the limitations set forth in this
          Agreement, any reasonable attorneys&#8217; or other reasonable fees or expenses incurred by such party in connection with any proceeding to the extent such party would have been indemnified for such fees or expenses if the indemnification provided for
          in this Article 3 was available to such party in accordance with its terms.</div>
        <div style="line-height: 1.25">&#160;</div>
        <div style="text-indent: 24.5pt; line-height: 1.25;">The parties hereto agree that it would not be just and equitable if contribution pursuant to this Section&#160;3.04
          were determined by pro rata allocation or by any other method of allocation that does not take into account the equitable considerations referred to in the immediately preceding paragraph. Notwithstanding the provisions of this Section&#160;3.04, no
          Shareholder shall be required to contribute, in the aggregate, any amount in excess of the amount by which the proceeds actually received by such Shareholder from the sale of the Registrable Securities subject to the proceeding exceeds the amount
          of any damages that such Shareholder has otherwise been required to pay by reason of such untrue or alleged untrue statement or omission or alleged omission, except in the case of fraud by such Shareholder. Each Shareholder&#8217;s obligation to
          contribute pursuant to this Section&#160;3.03 is several in the proportion that the proceeds of the offering received by such Shareholder bears to the total proceeds of the offering received by all such Shareholders and not joint.</div>
        <div style="line-height: 1.25">&#160;</div>
        <div style="text-indent: 24.5pt; line-height: 1.25;">No Person guilty of fraudulent misrepresentation (within the meaning of Section&#160;11(f) of the Securities Act) shall
          be entitled to contribution from any Person who was not guilty of such fraudulent misrepresentation. The indemnity and contribution agreements contained in this Article 3 are in addition to any liability that the Indemnifying Parties may have to
          the Indemnified Parties.</div>
        <div style="line-height: 1.25">&#160;</div>
        <div style="text-indent: 24.5pt; line-height: 1.25;">Section&#160;3.05.&#160;<font style="font-style: italic;">Other
            Indemnification</font>. Indemnification similar to that provided in this Article 3 (with appropriate modifications) shall be given by the Company and each Shareholder participating therein with respect to any required registration or other
          qualification of securities under any foreign, federal or state law or regulation or governmental authority other than the Securities Act.</div>
      </div>
      <div style="line-height: 1.25;">
        <div style="line-height: 1.25;">&#160;</div>
      </div>
      <div style="line-height: 1.25;">
        <div style="text-align: center; line-height: 1.25;">ARTICLE 4</div>
        <div style="text-align: center; line-height: 1.25;">TERMINATION&#160;OF&#160;REGISTRATION&#160;RIGHTS</div>
      </div>
      <div style="line-height: 1.25;">
        <div style="line-height: 1.25;"><br style="line-height: 1.25;">
        </div>
        <div style="text-indent: 24.5pt; line-height: 1.25;">Section&#160;4.01.&#160;<font style="font-style: italic;">Termination
            of Registration Rights</font>. The rights of any Shareholder to request registration or inclusion of Registrable Securities in any registration pursuant to this Agreement shall terminate upon the earlier to occur of: (a)&#160;the fifth anniversary
          of this Agreement, and (b)&#160;such time as Rule 144 or another similar exemption under the Securities Act is available for the sale of all such Shareholder&#8217;s Company Securities without limitation during a three-month period without registration.</div>
      </div>
      <div style="line-height: 1.25;">
        <div style="line-height: 1.25;"><br style="line-height: 1.25;">
        </div>
        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
          <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-weight: normal; font-style: normal;" class="BRPFPageNumber">A - 11</font></div>
          <div style="page-break-after: always;" class="BRPFPageBreak">
            <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
        </div>
        <div style="line-height: 1.25">&#160;</div>
        <div style="text-align: center; line-height: 1.25;">ARTICLE 5</div>
      </div>
      <div style="line-height: 1.25;">
        <div style="text-align: center; line-height: 1.25;">MISCELLANEOUS</div>
      </div>
      <div style="line-height: 1.25;">
        <div style="line-height: 1.25;"><br style="line-height: 1.25;">
        </div>
        <div style="text-indent: 24.5pt; line-height: 1.25;">Section&#160;5.01<font style="font-style: italic;">.
            Binding Effect; Assignability; Benefit.&#160;</font>(a)&#160;This Agreement shall inure to the benefit of and be binding upon the parties hereto and their respective heirs, successors, legal representatives and permitted assigns. Any Shareholder that
          ceases to own beneficially any Registrable Securities shall cease to be bound by the terms hereof (other than (i)&#160;the provisions of Article 3 applicable to such Shareholder with respect to any offering of Registrable Securities completed before
          the date such Shareholder ceased to own any Registrable Securities and (ii)&#160;this Article 5).</div>
        <div style="line-height: 1.25">&#160;</div>
        <div style="text-indent: 24.5pt; line-height: 1.25;">(b) Neither this Agreement nor any right, remedy, obligation or liability arising hereunder or by reason hereof
          shall be assignable by any party hereto pursuant to any Transfer of Registrable Securities or otherwise, except that each Shareholder may assign rights hereunder to any Permitted Transferee of such Shareholder. Any such Permitted Transferee shall
          (unless already bound hereby) execute and deliver to the Company an agreement to be bound by this Agreement in the form of Exhibit A hereto (a &#8220;<font style="font-weight: bold;">Joinder
            Agreement</font>&#8221;) and shall thenceforth be a &#8220;<font style="font-weight: bold;">Shareholder</font>&#8221;.</div>
      </div>
      <div style="line-height: 1.25;">
        <div style="line-height: 1.25">&#160;</div>
        <div style="text-indent: 24.5pt; line-height: 1.25;">(c) Nothing in this Agreement, expressed or implied, is intended to confer on any Person other than the parties
          hereto, and their respective heirs, successors, legal representatives and permitted assigns, any rights, remedies, obligations or liabilities under or by reason of this Agreement.</div>
      </div>
      <div style="line-height: 1.25;">
        <div style="line-height: 1.25;"><br style="line-height: 1.25;">
        </div>
        <div style="text-indent: 24.5pt; line-height: 1.25;">Section&#160;5.02.&#160;<font style="font-style: italic;">Notices</font>.
          All notices, requests and other communications (each, a &#8220;<font style="font-weight: bold;">Notice</font>&#8221;) to any party shall be in writing and shall be delivered in person, mailed by
          certified or registered mail, return receipt requested, or sent by facsimile transmission or email transmission so long as receipt of such email is requested and received,</div>
      </div>
      <div style="line-height: 1.25;">
        <div style="line-height: 1.25;">&#160;if to the Company to:</div>
      </div>
      <div style="line-height: 1.25;">
        <div style="line-height: 1.25">&#160;</div>
        <div style="text-indent: 48.95pt; line-height: 1.25;">Sol-Gel Technologies Ltd.</div>
      </div>
      <div style="line-height: 1.25;">
        <div style="text-indent: 48.95pt; line-height: 1.25;">7 Golda Meir St., Weizmann Science Park</div>
        <div style="text-indent: 48.95pt; line-height: 1.25;">Ness Ziona, 7403650 Israel</div>
        <div style="text-indent: 48.95pt; line-height: 1.25;">Fax: +972 8 931 3434</div>
        <div style="text-indent: 48.95pt; line-height: 1.25;">Attention: Gilad Mamlok</div>
        <div style="text-indent: 48.95pt; line-height: 1.25;">Email: gilad.mamlok@sol-gel.com</div>
      </div>
      <div style="line-height: 1.25;">
        <div style="line-height: 1.25">&#160;</div>
        <div style="text-indent: 24.5pt; line-height: 1.25;">with a copy to:</div>
      </div>
      <div style="line-height: 1.25;">
        <div style="line-height: 1.25;"><br style="line-height: 1.25;">
        </div>
        <div style="text-indent: 48.95pt; line-height: 1.25;">Gross, Kleinhendler, Hodak, Halevy, Greenberg &amp; Co.</div>
      </div>
      <div style="line-height: 1.25;">
        <div style="text-indent: 48.95pt; line-height: 1.25;">One Azrieli Center</div>
        <div style="text-indent: 48.95pt; line-height: 1.25;">Tel Aviv 67021, Israel</div>
        <div style="text-indent: 48.95pt; line-height: 1.25;">Facsimile: +972 3 607 4411</div>
        <div style="text-indent: 48.95pt; line-height: 1.25;">Attention: Gene Kleinhendler, Adv.</div>
        <div style="text-indent: 48.95pt; line-height: 1.25;">Email: gene@gkhlaw.com</div>
      </div>
      <div style="line-height: 1.25;">
        <div style="line-height: 1.25">&#160;</div>
        <div style="text-indent: 24.5pt; line-height: 1.25;">if to any Shareholder, at the address for such Shareholder listed on the signature pages below or otherwise
          provided to the Company as set forth below.</div>
        <div style="line-height: 1.25">&#160;</div>
        <div style="text-indent: 24.5pt; line-height: 1.25;">Any Notice shall be deemed received on the date of receipt by the recipient thereof if received prior to 5:00 p.m.
          in the place of receipt and such day is a Business Day in the place of receipt. Otherwise, such Notice shall be deemed not to have been received until the next succeeding Business Day in the place of receipt. Any Notice sent by facsimile
          transmission also shall be confirmed by certified or registered mail, return receipt requested, posted within one Business Day after the date of the sending of such facsimile transmission, or by personal delivery, whether courier or otherwise,
          made within two Business Days after the date of such facsimile transmission.</div>
        <div style="text-indent: 24.5pt; line-height: 1.25;"> <br>
        </div>
        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
          <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-weight: normal; font-style: normal;" class="BRPFPageNumber">A - 12</font></div>
          <div style="page-break-after: always;" class="BRPFPageBreak">
            <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
        </div>
        <div style="line-height: 1.25">&#160;</div>
        <div style="text-indent: 24.5pt; line-height: 1.25;">Any Person that becomes a Shareholder after the date hereof shall provide its address, fax number and email
          address to the Company.</div>
        <div style="line-height: 1.25">&#160;</div>
        <div style="text-indent: 24.5pt; line-height: 1.25;">Section&#160;5.03.&#160;<font style="font-style: italic;">Waiver;
            Amendment</font>. (a)&#160;The provisions of this Agreement, including the provisions of this sentence, may not be amended, modified or supplemented, and waivers or consents to departures from the provisions hereof may not be given without the
          written consent of holders of a majority of the Registrable Securities then outstanding;&#160;<font style="font-style: italic;">provided</font>, however, that in no event shall the
          obligations of any holder of Registrable Securities be materially increased or the rights of any Shareholder be adversely affected (without similarly adversely affecting the rights of all Shareholders), except upon the written consent of such
          holder. Notwithstanding the foregoing, a waiver or consent to depart from the provisions hereof with respect to a matter that relates exclusively to the rights of holders of Registrable Securities whose securities are being sold pursuant to a
          Registration Statement and that does not directly or indirectly affect the rights of other holders of Registrable Securities may be given by holders of at least a majority of the Registrable Securities being sold by such holders pursuant to such
          Registration Statement.</div>
      </div>
      <div style="line-height: 1.25;">
        <div style="line-height: 1.25;">&#160;</div>
      </div>
      <div style="line-height: 1.25;">
        <div style="text-indent: 24.5pt; line-height: 1.25;">Section&#160;5.04.&#160;<font style="font-style: italic;">Governing
            Law</font>. This Agreement shall be governed by, and construed and enforced in accordance with, the laws of the State of Israel, without regard to the conflicts of laws rules.</div>
      </div>
      <div style="line-height: 1.25;">
        <div style="line-height: 1.25;"><br style="line-height: 1.25;">
        </div>
        <div style="text-indent: 24.5pt; line-height: 1.25;">Section&#160;5.05.&#160;<font style="font-style: italic;">Jurisdiction</font>.
          The parties hereby agree that any suit, action or proceeding seeking to enforce any provision of, or based on any matter arising out of or in connection with, this Agreement or the transactions contemplated hereby shall be brought in the
          competent courts located in Tel Aviv-Jaffa, and that any cause of action arising out of this Agreement shall be deemed to have arisen from a transaction of business in the State of Israel, and each of the parties hereby irrevocably consents to
          the jurisdiction of such courts (and of the appropriate appellate courts therefrom) in any such suit, action or proceeding and irrevocably waives, to the fullest extent permitted by law, any objection that it may now or hereafter have to the
          laying of the venue of any such suit, action or proceeding in any such court or that any such suit, action or proceeding which is brought in any such court has been brought in an inconvenient form. Process in any such suit, action or proceeding
          may be served on any party anywhere in the world, whether within or without the jurisdiction of any such court. Without limiting the foregoing, each party agrees that service of process on such party as provided in Section&#160;5.02 shall be deemed
          effective service of process on such party.</div>
        <div style="line-height: 1.25">&#160;</div>
        <div style="text-indent: 24.5pt; line-height: 1.25;">Section&#160;5.06.&#160;<font style="font-style: italic;">Specific
            Enforcement</font>. Each party hereto acknowledges that the remedies at law of the other parties for a breach or threatened breach of this Agreement would be inadequate and, in recognition of this fact, any party to this Agreement, without
          posting any bond or furnishing other security, and in addition to all other remedies that may be available, shall be entitled to obtain equitable relief in the form of specific performance, a temporary restraining order, a temporary or permanent
          injunction or any other equitable remedy that may then be available.</div>
        <div style="line-height: 1.25">&#160;</div>
        <div style="text-indent: 24.5pt; line-height: 1.25;">Section&#160;5.07.&#160;<font style="font-style: italic;">Counterparts;
            Effectiveness</font>. This Agreement may be executed (including by facsimile or other electronic image scan transmission) with counterpart signature pages or in any number of counterparts, each of which shall be deemed to be an original, and
          all of which shall, taken together, be considered one and the same agreement, it being understood that each party need not sign the same counterpart. This Agreement shall become effective when each party hereto shall have executed and delivered
          this Agreement. Until and unless each party has executed and delivered this Agreement, this Agreement shall have no effect and no party shall have any right or obligation hereunder (whether by virtue of any other oral or written agreement or
          other communication).</div>
        <div style="line-height: 1.25">&#160;</div>
        <div style="text-indent: 24.5pt; line-height: 1.25;">Section&#160;5.08.&#160;<font style="font-style: italic;">Entire
            Agreement</font>. This Agreement constitutes the entire agreement and understanding among the parties hereto and supersedes all prior and contemporaneous agreements and understandings, both oral and written, among the parties hereto with
          respect to the subject matter hereof.</div>
        <div style="text-indent: 24.5pt; line-height: 1.25;"> <br>
        </div>
        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
          <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-weight: normal; font-style: normal;" class="BRPFPageNumber">A - 13</font></div>
          <div style="page-break-after: always;" class="BRPFPageBreak">
            <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
        </div>
        <div style="line-height: 1.25">&#160;</div>
        <div style="text-indent: 24.5pt; line-height: 1.25;">Section&#160;5.09.&#160;<font style="font-style: italic;">Severability</font>.
          If any term, provision, covenant or restriction of this Agreement is held by a court of competent jurisdiction or other authority to be invalid, void or unenforceable, the remainder of the terms, provisions, covenants and restrictions of this
          Agreement shall remain in full force and effect and shall in no way be affected, impaired or invalidated so long as the economic or legal substance of the transactions contemplated hereby is not affected in any manner materially adverse to any
          party. Upon such a determination, the parties shall negotiate in good faith to modify this Agreement so as to effect the original intent of the parties as closely as possible in an acceptable manner so that the transactions contemplated hereby be
          consummated as originally contemplated to the fullest extent possible.</div>
        <div style="line-height: 1.25">&#160;</div>
        <div style="text-indent: 24.5pt; line-height: 1.25;">Section&#160;5.10<font style="font-style: italic;">.
            Other Registration Rights.&#160;</font>From and after the date of this Agreement, the Company shall not, without the prior written consent of holders of a majority of the Registrable Securities, enter into any agreement with any holder or
          prospective holder of any securities of the Company giving such holder or prospective holder any registration rights the terms of which would reduce the amount of Registrable Securities the Shareholders can include in any registration statement,
          unless such rights are subordinate to those of the Shareholders hereunder.</div>
        <div style="line-height: 1.25">&#160;</div>
        <div style="text-indent: 24.5pt; line-height: 1.25;">Section&#160;5.11<font style="font-style: italic;">.
            Confidentiality.&#160;</font>Each Shareholder agrees that any notice received pursuant to this Agreement, including any notice of a proposed underwritten public offering or postponement of an offering or effecting of a registration, is confidential
          information and that any trading in securities of the Company following receipt of such information may only be done in compliance with all applicable securities laws.</div>
        <div style="line-height: 1.25">&#160;</div>
        <div style="text-indent: 24.5pt; line-height: 1.25;">Section&#160;5.12<font style="font-style: italic;">.
            Independent Nature of Shareholders&#8217; Obligations and Rights.&#160;</font>The obligations of each Shareholder hereunder are several and not joint with the obligations of any other Shareholder hereunder, and no Shareholder shall be responsible in any
          way for the performance of the obligations of any other Shareholder hereunder. Nothing contained herein or in any other agreement or document delivered at any closing, and no action taken by any Shareholder pursuant hereto or thereto, shall be
          deemed to constitute the Shareholders as a partnership, an association, a joint venture or any other kind of entity, or create a presumption that the Shareholders are in any way acting in concert with respect to such obligations or the
          transactions contemplated by this Agreement. Each Shareholder shall be entitled to protect and enforce its rights, including the rights arising out of this Agreement, and it shall not be necessary for any other Shareholder to be joined as an
          additional party in any proceeding for such purpose.</div>
      </div>
      <div style="line-height: 1.25;">
        <div style="line-height: 1.25; text-align: center;">
          <div style="line-height: 1.25">&#160;</div>
          <div style="line-height: 1.25; font-style: italic;">[Signature pages follow.]</div>
          <div style="line-height: 1.25; font-style: italic;"> <br>
          </div>
        </div>
        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
          <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-weight: normal; font-style: normal;" class="BRPFPageNumber">A - 14</font></div>
          <div style="page-break-after: always;" class="BRPFPageBreak">
            <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
        </div>
        <div style="line-height: 1.25;"><br style="line-height: 1.25;">
        </div>
      </div>
      <div style="line-height: 1.25;">
        <div style="text-indent: 24.4pt; line-height: 1.25;">IN WITNESS WHEREOF, the parties hereto have duly executed this Agreement or have caused this Agreement to be duly
          executed by their respective authorized officers as of the day and year first above written.</div>
      </div>
      <div style="line-height: 1.25;">
        <div style="line-height: 1.25;">&#160;</div>
      </div>
      <table cellspacing="0" cellpadding="0" border="0" align="right" id="z4b21f5b61c7b416dae0efababe075881" style="width: 50%; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">

          <tr>
            <td style="width: 100%; vertical-align: top;" colspan="3">
              <div style="line-height: 1.25; font-weight: bold;">SOL-GEL TECHNOLOGY LTD.</div>
            </td>
          </tr>
          <tr>
            <td style="width: 8.36%; vertical-align: middle;">&#160;</td>
            <td style="width: 91.64%; vertical-align: middle;" colspan="2">&#160;</td>
          </tr>
          <tr>
            <td style="width: 8.36%; vertical-align: top;">
              <div style="line-height: 1.25;">By:</div>
            </td>
            <td style="width: 1.45%; vertical-align: bottom; border-bottom: #000000 2px solid;">&#160;</td>
            <td style="width: 90.19%; vertical-align: top; border-bottom: #000000 2px solid;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
          </tr>
          <tr>
            <td style="width: 8.36%; vertical-align: top;">&#160;</td>
            <td style="width: 1.45%; vertical-align: bottom;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 90.19%; vertical-align: bottom;">
              <div style="line-height: 1.25;">Name: Alon Seri &#8211; Levy</div>
            </td>
          </tr>
          <tr>
            <td style="width: 8.36%; vertical-align: top;">&#160;</td>
            <td style="width: 1.45%; vertical-align: bottom;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 90.19%; vertical-align: bottom;">
              <div style="line-height: 1.25;">Title: CEO</div>
            </td>
          </tr>
          <tr>
            <td style="width: 8.36%; vertical-align: middle;">&#160;</td>
            <td style="width: 91.64%; vertical-align: middle;" colspan="2">&#160;</td>
          </tr>
          <tr>
            <td style="width: 8.36%; vertical-align: top;">
              <div style="line-height: 1.25;">By:</div>
            </td>
            <td style="width: 1.45%; vertical-align: bottom; border-bottom: #000000 2px solid;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 90.19%; vertical-align: top; border-bottom: #000000 2px solid;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
          </tr>
          <tr>
            <td style="width: 8.36%; vertical-align: top;">&#160;</td>
            <td style="width: 1.45%; vertical-align: bottom;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 90.19%; vertical-align: bottom;">
              <div style="line-height: 1.25;">Name: Gilad Mamlok</div>
            </td>
          </tr>
          <tr>
            <td style="width: 8.36%; vertical-align: top;">&#160;</td>
            <td style="width: 1.45%; vertical-align: bottom;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 90.19%; vertical-align: bottom;">
              <div style="line-height: 1.25;">Title: CFO</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25; clear: both;">
        <div style="line-height: 1.25;">&#160;</div>
      </div>
      <table cellspacing="0" cellpadding="0" border="0" align="right" id="z0c70e895c6554227a3fcbc356523216e" style="width: 50%; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">

          <tr>
            <td style="width: 100%; vertical-align: top;" colspan="3">
              <div style="line-height: 1.25; font-weight: bold;">M. ARKIN DERMATOLOGY LTD.</div>
            </td>
          </tr>
          <tr>
            <td style="width: 8.39%; vertical-align: middle;">&#160;</td>
            <td style="width: 91.61%; vertical-align: middle;" colspan="2">&#160;</td>
          </tr>
          <tr>
            <td style="width: 8.39%; vertical-align: top;">
              <div style="line-height: 1.25;">By:</div>
            </td>
            <td style="width: 1.45%; vertical-align: bottom; border-bottom: #000000 2px solid;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 90.16%; vertical-align: top; border-bottom: #000000 2px solid;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
          </tr>
          <tr>
            <td style="width: 8.39%; vertical-align: top;">&#160;</td>
            <td style="width: 1.45%; vertical-align: bottom;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 90.16%; vertical-align: bottom;">
              <div style="line-height: 1.25;">Name: Moshe Arkin</div>
            </td>
          </tr>
          <tr>
            <td style="width: 8.39%; vertical-align: top;">&#160;</td>
            <td style="width: 1.45%; vertical-align: bottom;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 90.16%; vertical-align: bottom;">
              <div style="line-height: 1.25;">Title: Chairman</div>
            </td>
          </tr>
          <tr>
            <td style="width: 8.39%; vertical-align: top;" rowspan="1" colspan="2">&#160;&#160;</td>
            <td style="width: 90.16%; vertical-align: bottom;" rowspan="1">&#160;
              <div style="line-height: 1.25; clear: both;">
                <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><u>Address for Notices</u>:</div>
              </div>
              <div style="line-height: 1.25;">
                <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">7 Golda Meir St., Ness Ziona 7403650</div>
                <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">Israel</div>
                <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">Attn: Gilad Mamlok</div>
                <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">Email: <u>gilad.mamlok@sol-gel.com</u></div>
              </div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25;">
        <div style="line-height: 1.25;"><br style="line-height: 1.25;">
        </div>
        <div style="line-height: 1.25;">&#160;<br style="line-height: 1.25;">
        </div>
        <div style="line-height: 1.25;"><br style="line-height: 1.25;">
        </div>
        <div style="line-height: 1.25;"><br style="line-height: 1.25;">
        </div>
        <div style="line-height: 1.25;"><br style="line-height: 1.25;">
        </div>
        <div style="line-height: 1.25;"><br style="line-height: 1.25;">
        </div>
        <div style="line-height: 1.25;"><br style="line-height: 1.25;">
        </div>
        <div style="line-height: 1.25;"><br style="line-height: 1.25;">
        </div>
        <div style="line-height: 1.25;"><br style="line-height: 1.25;">
        </div>
        <div style="line-height: 1.25;"><br style="line-height: 1.25;">
        </div>
        <div style="line-height: 1.25;"><br style="line-height: 1.25;">
        </div>
        <div style="line-height: 1.25;"><br style="line-height: 1.25;">
        </div>
        <div style="line-height: 1.25;"><br style="line-height: 1.25;">
        </div>
      </div>
      <div style="line-height: 1.25;">
        <div style="text-align: center; line-height: 1.25;">[<font style="font-style: italic;">Signature page to the Registration
            Rights Agreement</font>]</div>
        <div style="text-align: center; line-height: 1.25;"> <br>
        </div>
        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
          <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-weight: normal; font-style: normal;" class="BRPFPageNumber">A - 15</font></div>
          <div style="page-break-after: always;" class="BRPFPageBreak">
            <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
        </div>
        <br>
      </div>
      <div style="line-height: 1.25;">
        <div style="text-align: center; line-height: 1.25;">EXHIBIT A</div>
      </div>
      <div style="line-height: 1.25;">
        <div style="text-align: center; line-height: 1.25;"><u>JOINDER TO REGISTRATION RIGHTS AGREEMENT</u></div>
      </div>
      <div style="line-height: 1.25;">
        <div style="line-height: 1.25;"><br style="line-height: 1.25;">
        </div>
        <div style="text-indent: 24.5pt; line-height: 1.25;">This Joinder Agreement (this &#8220;<font style="font-weight: bold;">Joinder Agreement</font>&#8221;) is made as of the date written below by the undersigned (the &#8220;<font style="font-weight: bold;">Joining Party</font>&#8221;) in accordance
          with the Registration Rights Agreement dated as of February 5, 2018 (as the same may be amended from time to time, the &#8220;<font style="font-weight: bold;">Registration Rights Agreement</font>&#8221;),
          among Sol-Gel Technologies Ltd. and the Shareholders party thereto. Capitalized terms used, but not defined, herein shall have the meaning ascribed to such terms in the Registration Rights Agreement.</div>
        <div style="line-height: 1.25">&#160;</div>
        <div style="text-indent: 24.5pt; line-height: 1.25;">The Joining Party hereby acknowledges, agrees and confirms that, by its execution of this Joinder Agreement, the
          Joining Party shall be deemed to be a party to the Registration Rights Agreement as of the date hereof as a &#8220;<font style="font-weight: bold;">Permitted Transferee</font>&#8221; of a
          Shareholder thereto, and shall have all of the rights and obligations of a &#8220;<font style="font-weight: bold;">Shareholder</font>&#8221; thereunder as if it had executed the Registration
          Rights Agreement. The Joining Party hereby ratifies, as of the date hereof, and agrees to be bound by, all of the terms, provisions and conditions contained in the Registration Rights Agreement (including, without limitation, Section&#160;5.01
          thereof).</div>
        <div style="line-height: 1.25">&#160;</div>
        <div style="text-indent: 24.5pt; line-height: 1.25;">IN WITNESS WHEREOF, the undersigned has executed this Joinder Agreement as of the date written below.</div>
        <div style="text-indent: 24.5pt; line-height: 1.25;"> <br>
        </div>
      </div>
      <table cellspacing="0" cellpadding="0" id="z472edec69e39420a9726c73ebc18a1b8" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 47.01%; vertical-align: top;">
              <div style="line-height: 1.25;">Date:&#160;<u>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</u><u>&#160;</u><u>&#160;&#160;&#160;&#160;&#160;&#160;&#160;</u>&#160;,&#160;&#160;<u>&#160;&#160;&#160;&#160;&#160;</u><u>&#160;</u><u>&#160;&#160;&#160;&#160;&#160;&#160;&#160;</u>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <br>
                </div>
            </td>
            <td style="width: 1%; vertical-align: bottom;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 4%; vertical-align: top;">&#160;</td>
            <td style="width: 0.89%; vertical-align: bottom;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 47.09%; vertical-align: top;" colspan="3">&#160;</td>
          </tr>
          <tr>
            <td style="width: 47.01%; vertical-align: middle;">&#160;</td>
            <td style="width: 52.99%; vertical-align: middle;" colspan="6">&#160;</td>
          </tr>
          <tr>
            <td style="width: 47.01%; vertical-align: top;">&#160;</td>
            <td style="width: 1%; vertical-align: bottom;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 51.99%; vertical-align: top;" colspan="5">
              <div style="line-height: 1.25;">[NAME OF JOINING PARTY]</div>
            </td>
          </tr>
          <tr>
            <td style="width: 47.01%; vertical-align: middle;">&#160;</td>
            <td style="width: 5%; vertical-align: middle;" colspan="2">&#160;</td>
            <td style="width: 1%; vertical-align: middle;" colspan="2">&#160;</td>
            <td style="width: 46.99%; vertical-align: middle;" colspan="2">&#160;</td>
          </tr>
          <tr>
            <td style="width: 47.01%; vertical-align: top;">&#160;</td>
            <td style="width: 1%; vertical-align: bottom;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 4%; vertical-align: top;">
              <div style="text-indent: -12pt; margin-left: 12pt; line-height: 1.25;">By:</div>
            </td>
            <td style="width: 0.89%; vertical-align: bottom;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 0.1%; vertical-align: top;">&#160;</td>
            <td style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 46%; vertical-align: top; border-bottom: #000000 2px solid;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
          </tr>
          <tr>
            <td style="width: 47.01%; vertical-align: top;">&#160;</td>
            <td style="width: 1%; vertical-align: bottom;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 4%; vertical-align: top;">&#160;</td>
            <td style="width: 0.89%; vertical-align: bottom;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 0.1%; vertical-align: top;">&#160;</td>
            <td style="width: 1%; vertical-align: bottom;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 46%; vertical-align: top;">
              <div style="line-height: 1.25;">Name:</div>
            </td>
          </tr>
          <tr>
            <td style="width: 47.01%; vertical-align: top;">&#160;</td>
            <td style="width: 1%; vertical-align: bottom;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 4%; vertical-align: bottom;">&#160;</td>
            <td style="width: 0.89%; vertical-align: bottom;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 0.1%; vertical-align: top;">&#160;</td>
            <td style="width: 1%; vertical-align: bottom;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 46%; vertical-align: bottom;">
              <div style="line-height: 1.25;">Title:</div>
            </td>
          </tr>
          <tr>
            <td style="width: 47.01%; vertical-align: middle;">&#160;</td>
            <td style="width: 52.99%; vertical-align: middle;" colspan="6">&#160;</td>
          </tr>
          <tr>
            <td style="width: 47.01%; vertical-align: top;">&#160;</td>
            <td style="width: 1%; vertical-align: bottom;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 51.99%; vertical-align: bottom;" colspan="5">
              <div style="line-height: 1.25;">Address for Notices:</div>
            </td>
          </tr>
          <tr>
            <td style="width: 47.01%; vertical-align: top;">&#160;</td>
            <td style="width: 1%; vertical-align: bottom;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 51.99%; vertical-align: bottom;" colspan="5">
              <div style="line-height: 1.25;">[Address]</div>
            </td>
          </tr>
          <tr>
            <td style="width: 47.01%; vertical-align: top;">&#160;</td>
            <td style="width: 1%; vertical-align: bottom;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 51.99%; vertical-align: bottom;" colspan="5">
              <div style="line-height: 1.25;">[Fax number]</div>
            </td>
          </tr>
          <tr>
            <td style="width: 47.01%; vertical-align: top;">&#160;</td>
            <td style="width: 1%; vertical-align: bottom;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 51.99%; vertical-align: bottom;" colspan="5">
              <div style="line-height: 1.25;">[Email address]</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25;">
        <div style="line-height: 1.25;">&#160;</div>
        <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><font style="font-weight: normal; font-style: normal;" class="BRPFPageNumber">A - 16</font> </div>
      </div>
      <div style="line-height: 1.25;">
        <hr align="center" style="border: none; border-bottom: 4px solid black; border-top: 1px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;"></div>
      <div style="line-height: 1.25">&#160;</div>
    </div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-weight: 400;"><br>
    </div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.2
<SEQUENCE>3
<FILENAME>exhibit_99-2.htm
<DESCRIPTION>EXHIBIT 99.2
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Z-K GLOBAL
         Document created using Broadridge PROfile 23.1.1.5115
         Copyright 1995 - 2023 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;">
  <div>
    <div style="line-height: 1.25;">
      <hr align="center" style="border: none; border-bottom: 1px solid black; border-top: 4px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;"></div>
    <div style="line-height: 1.25;">
      <div style="text-align: right; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-weight: 400;"><u><font style="font-weight: bold;"> Exhibit 99.2</font></u><br>
      </div>
      <div style="text-align: center; margin-right: 89.25pt; margin-left: 88.4pt; line-height: 1.25; font-weight: bold;"> <br>
      </div>
      <div style="text-align: center; margin-right: 89.25pt; margin-left: 88.4pt; line-height: 1.25; font-weight: bold;">Important Notice Regarding the Availability of Proxy Materials for the
        Special Meeting:</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: center; margin-right: 89.25pt; margin-left: 88.4pt; line-height: 1.25;">The Notice and Proxy Statement is available at www.proxyvote.com.</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="line-height: 1.25;">
        <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; color: #000000; width: 100%;" id="z1c9130efd65744afa771b4f7d948506c">

            <tr>
              <td style="border-top: 1px dashed #000000; width: 100%;">
                <div>&#160;
                  <div style="text-align: right; margin-right: 24.55pt; line-height: 1.25;">V00166-S63073</div>
                </div>
              </td>
            </tr>

        </table>
      </div>
      <div style="line-height: 1.25;">
        <div style="border: #000000 2px solid; padding: 5px; width: 99%;">
          <div>
            <div style="text-align: center; margin-right: 89.25pt; margin-left: 88.35pt; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-size: 12pt; font-weight: bold; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">SOL-GEL TECHNOLOGIES LTD.</div>
            <div style="line-height: 1.25">&#160;</div>
            <div style="text-align: center; margin-right: 175.15pt; margin-left: 174.25pt; line-height: 1.25; font-weight: bold;">Proxy for Special Meeting of Shareholders on March 30, 2023</div>
            <div style="line-height: 1.25">&#160;</div>
            <div style="text-align: center; margin-right: 89.25pt; margin-left: 88.3pt; line-height: 1.25; font-weight: bold;">Solicited on Behalf of the Board of Directors</div>
            <div style="line-height: 1.25">&#160;</div>
            <div style="text-align: justify; margin-right: 23.8pt; margin-left: 23pt; line-height: 1.25;">The undersigned hereby appoints Alon Seri-Levy and Gilad Mamlok, and each of them, with
              full power of substitution and power to act alone, as proxies to vote all the ordinary shares which the undersigned would be entitled to vote if personally present and acting at the Special Meeting of Shareholders of Sol-Gel Technologies
              Ltd., to be held at 4:00 PM (Israel time) on March 30, 2023 at 7 Golda Meir St., Weizmann Science Park, Ness Ziona, 7403650, Israel, and at any adjournments or postponements thereof, as follows:</div>
            <div style="line-height: 1.25; text-align: justify;">&#160;</div>
            <div style="text-align: justify; margin-right: 23.95pt; margin-left: 23pt; line-height: 1.25; font-weight: bold;">This proxy, when properly executed, will be voted in the manner
              directed herein. If no such direction is made, this proxy will be voted in accordance with the Board of Directors' recommendations.</div>
            <div style="text-align: justify; margin-right: 23.95pt; margin-left: 23pt; line-height: 1.25; font-weight: bold;"> <br>
            </div>
            <div style="text-align: center; margin-right: 23.95pt; margin-left: 23pt; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-weight: bold;">
              <div style="margin-right: 89.25pt; margin-left: 88.4pt; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Continued and to be signed on reverse side</div>
            </div>
            <div style="line-height: 1.25;"></div>
          </div>
        </div>
      </div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: right; margin-right: 24.55pt; line-height: 1.25;">
        <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; color: #000000; width: 100%;" id="z3eabb46a434f4f57ba287dc779c894df">

            <tr>
              <td style="width: 50%; text-align: left; vertical-align: top;">
                <div>
                  <div style="margin-left: 41pt; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-style: italic;"> <br>
                  </div>
                  <div style="margin-left: 41pt; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-style: italic;"> <br>
                  </div>
                  <div style="margin-left: 41pt; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-style: italic;"> <br>
                  </div>
                  <div style="margin-left: 41pt; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-style: italic;"> <br>
                  </div>
                  <div style="margin-left: 41pt; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-style: italic;"> <br>
                  </div>
                  <div style="margin-left: 41pt; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-style: italic;">SOL-GEL TECHNOLOGIES LTD.</div>
                  <div style="margin-left: 41pt; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-style: italic;">7 GOLDA MEIR ST., WEIZMANN SCIENCE PARK </div>
                  <div style="margin-left: 41pt; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-style: italic;">NESS ZIONA, 7403650, ISRAEL</div>
                </div>
              </td>
              <td style="width: 50.00%;">
                <div style="text-align: center;"> <img src="scan.jpg"></div>
                <div>&#160;
                  <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-weight: bold;">VOTE BY INTERNET -&#160;<u>www.proxyvote.com</u> or scan the QR Barcode above</div>
                  <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">Use the Internet to transmit your voting instructions and for electronic delivery of information up until 11:59
                    p.m. Eastern Time on March 29, 2023. Have your proxy card in hand when you access the web site and follow the instructions to obtain your records and to create an electronic voting instruction form.</div>
                  <div style="line-height: 1.25;">&#160;</div>
                  <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-weight: bold;">ELECTRONIC DELIVERY OF FUTURE PROXY MATERIALS</div>
                  <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">If you would like to reduce the costs incurred by our company in mailing proxy materials, you can consent to
                    receiving all future proxy statements, proxy cards and annual reports electronically via e-mail or the Internet. To sign up for electronic delivery, please follow the instructions above to vote using the Internet and, when prompted,
                    indicate that you agree to receive or access proxy materials electronically in future years.</div>
                  <div style="line-height: 1.25;">&#160;</div>
                  <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-weight: bold;">VOTE BY PHONE - 1-800-690-6903</div>
                  <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">Use any touch-tone telephone to transmit your voting instructions up until 11:59 p.m. Eastern Time on March 29,
                    2023. Have your proxy card in hand when you call and then follow the instructions.</div>
                  <div style="line-height: 1.25;">&#160;</div>
                  <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-weight: bold;">VOTE BY MAIL</div>
                  <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">Mark, sign and date your proxy card and return it in the postage-paid envelope we have provided or return it to
                    Vote Processing, c/o Broadridge, 51 Mercedes Way, Edgewood, NY 11717.</div>
                  <div style="line-height: 1.25;">
                    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
                    </div>
                  </div>
                </div>
              </td>
            </tr>

        </table>
        <br>
        <div>
          <div style="text-align: left; margin-left: 5pt; line-height: 1.25;">TO VOTE, MARK BLOCKS BELOW IN BLUE OR BLACK INK AS FOLLOWS:</div>
          <div style="line-height: 1.25">&#160;</div>
        </div>
        <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; color: #000000; width: 100%;">

            <tr>
              <td style="width: 10%;" rowspan="1">&#160;</td>
              <td style="width: 55%; text-align: right;" colspan="1" rowspan="1">&#160;V00165-S63073&#160;&#160;&#160;&#160;&#160;&#160;&#160; <br>
              </td>
              <td style="width: 35%; text-align: right;" rowspan="1">
                <div style="margin-left: 5pt; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">KEEP THIS PORTION FOR YOUR RECORDS</div>
              </td>
            </tr>
            <tr>
              <td style="border-top: 1px dashed rgb(0, 0, 0); width: 10%;"><br>
              </td>
              <td style="border-top: 1px dashed rgb(0, 0, 0); width: 55%;" colspan="1">
                <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-weight: bold; margin-left: 72pt;">THIS PROXY CARD IS VALID ONLY WHEN SIGNED AND DATED.</div>
              </td>
              <td style="border-top: 1px dashed rgb(0, 0, 0); width: 35%;">
                <div style="text-align: right;">&#160;DETACH AND RETURN THIS PORTION ONLY</div>
              </td>
            </tr>

        </table>
      </div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="line-height: 1.25">
        <div style="border: #000000 2px solid; padding: 5px; width: 99%;">
          <div>&#160;
            <div style="line-height: 1.25;">
              <div style="line-height: 1.25">
                <div style="line-height: 1.25; font-weight: bold;">SOL-GEL TECHNOLOGIES LTD.</div>
              </div>
              <br>
              <div style="line-height: 1.25;">
                <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-weight: bold; margin-left: 27pt;">THE BOARD OF DIRECTORS RECOMMENDS A VOTE "FOR" PROPOSALS 1 AND 2.</div>
                <div style="line-height: 1.25; font-weight: bold;"> <br>
                </div>
                <div style="line-height: 1.25; font-weight: bold;">
                  <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; color: #000000; width: 100%;">

                      <tr>
                        <td style="width: 6.91%;" rowspan="1">&#160;</td>
                        <td rowspan="1" colspan="2">&#160;</td>
                        <td style="width: 8%;" rowspan="1">
                          <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-weight: bold;">For <br>
                          </div>
                        </td>
                        <td style="width: 8%; text-align: center; font-weight: bold;" rowspan="1">&#160;Against </td>
                        <td style="width: 8%; text-align: center; font-weight: bold;" rowspan="1">&#160;Abstain</td>
                      </tr>
                      <tr>
                        <td style="width: 6.91%; text-align: center; vertical-align: top;">
                          <div>&#160;<font style="font-family: 'Times New Roman',Times,serif;">1.</font>&#160;&#160; <br>
                          </div>
                        </td>
                        <td rowspan="1" colspan="2">To approve a private placement to M. Arkin Dermatology Ltd., the Company&#8217;s controlling shareholder.</td>
                        <td style="width: 8%;">
                          <div style="text-align: center;">&#160;&#9744;</div>
                        </td>
                        <td style="width: 8%;">
                          <div style="text-align: center;">&#9744; <br>
                          </div>
                        </td>
                        <td style="width: 8%;">
                          <div style="text-align: center;">&#9744; <br>
                          </div>
                          <div style="text-align: center;"> <br>
                          </div>
                        </td>
                      </tr>
                      <tr>
                        <td style="width: 6.91%;">
                          <div>&#160;</div>
                        </td>
                        <td style="width: 7%;">
                          <div>&#160;</div>
                        </td>
                        <td style="width: 62%;">
                          <div>&#160;</div>
                        </td>
                        <td style="width: 8%;">
                          <div style="text-align: center; font-weight: bold;">Yes <br>
                          </div>
                        </td>
                        <td style="width: 8%;">
                          <div style="text-align: center; font-weight: bold;">&#160;No</div>
                        </td>
                        <td style="width: 8%;">
                          <div style="text-align: center;">&#160;</div>
                        </td>
                      </tr>
                      <tr>
                        <td style="width: 6.91%;">
                          <div>&#160;</div>
                        </td>
                        <td style="width: 7%; text-align: left; vertical-align: top;">
                          <div>1a.<br>
                          </div>
                        </td>
                        <td style="width: 62%;">Do you have a personal interest in approval of proposal 1 above? <font style="font-weight: bold; font-style: italic;"><u>Response required for
                              vote to be counted</u></font></td>
                        <td style="width: 8%;">
                          <div style="text-align: center;">&#160;&#9744;</div>
                        </td>
                        <td style="width: 8%;">
                          <div style="text-align: center;">&#160;&#9744;</div>
                        </td>
                        <td style="width: 8%;">
                          <div style="text-align: center;">&#160;</div>
                          <div style="text-align: center;"> <br>
                          </div>
                        </td>
                      </tr>
                      <tr>
                        <td style="width: 6.91%;">
                          <div>&#160;</div>
                        </td>
                        <td style="width: 7%;">
                          <div>&#160;</div>
                        </td>
                        <td style="width: 62%;">
                          <div>&#160;</div>
                        </td>
                        <td style="width: 8%;">
                          <div style="text-align: center; font-weight: bold;">&#160;For </div>
                        </td>
                        <td style="width: 8%;">
                          <div style="text-align: center; font-weight: bold;">&#160; Against </div>
                        </td>
                        <td style="width: 8%;">
                          <div style="text-align: center; font-weight: bold;">&#160; Abstain</div>
                        </td>
                      </tr>
                      <tr>
                        <td style="width: 6.91%; text-align: center; vertical-align: top;">
                          <div>&#160;<font style="font-family: 'Times New Roman',Times,serif;">2.</font> <br>
                          </div>
                        </td>
                        <td rowspan="1" colspan="2">
                          <div style="line-height: 1.25;">
                            <div style="text-align: left; line-height: 1.25;">To approve the renewal of the Registration Rights Agreement between the Company and M. Arkin
                                Dermatology Ltd.</div>
                          </div>
                        </td>
                        <td style="width: 8%;">
                          <div style="text-align: center;">&#160;&#9744;</div>
                        </td>
                        <td style="width: 8%;">
                          <div style="text-align: center;">&#9744; <br>
                          </div>
                        </td>
                        <td style="width: 8%;">
                          <div style="text-align: center;">&#9744; <br>
                          </div>
                          <div style="text-align: center;"> <br>
                          </div>
                        </td>
                      </tr>
                      <tr>
                        <td style="width: 6.91%;">
                          <div>&#160;</div>
                        </td>
                        <td style="width: 7%;">
                          <div>&#160;</div>
                        </td>
                        <td style="width: 62%;">
                          <div>&#160;</div>
                        </td>
                        <td style="width: 8%;">
                          <div style="text-align: center; font-weight: bold;">&#160;Yes</div>
                        </td>
                        <td style="width: 8%;">
                          <div style="text-align: center; font-weight: bold;">&#160; No</div>
                        </td>
                        <td style="width: 8%;">
                          <div style="text-align: center;">&#160;</div>
                        </td>
                      </tr>
                      <tr>
                        <td style="width: 6.91%;">
                          <div>&#160;</div>
                        </td>
                        <td style="width: 7%; text-align: left; vertical-align: top;">
                          <div>2a.</div>
                        </td>
                        <td style="width: 62%;">Do you have a personal interest in approval of proposal 2 above? <font style="font-weight: bold; font-style: italic;"><u>Response required for
                              vote to be counted</u>.</font></td>
                        <td style="width: 8%;">
                          <div style="text-align: center;">&#160;&#9744;</div>
                        </td>
                        <td style="width: 8%;">
                          <div style="text-align: center;">&#160;&#9744;</div>
                        </td>
                        <td style="width: 8%;">
                          <div style="text-align: center;">&#160;</div>
                        </td>
                      </tr>
                      <tr>
                        <td style="width: 6.91%;" rowspan="1">&#160;</td>
                        <td style="width: 7%;" rowspan="1">&#160;</td>
                        <td style="width: 62%;" rowspan="1">&#160;</td>
                        <td style="width: 8%;" rowspan="1">&#160;</td>
                        <td style="width: 8%;" rowspan="1">&#160;</td>
                        <td style="width: 8%;" rowspan="1">&#160;</td>
                      </tr>

                  </table>
                  <table cellspacing="0" cellpadding="0" border="0" style="width: 50%; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">

                      <tr>
                        <td style="width: 60%;" rowspan="1">
                          <div style="text-align: left; line-height: 1.25;">Please indicate if you plan to attend this meeting.</div>
                        </td>
                        <td style="width: 20%; text-align: center; font-weight: bold;" rowspan="1">
                          <div>&#160; Yes</div>
                          <div>&#160;&#9744; </div>
                        </td>
                        <td style="width: 20%; text-align: center; font-weight: bold;" rowspan="1">
                          <div>&#160;&#160; No</div>
                          <div>&#160;&#9744; </div>
                        </td>
                      </tr>

                  </table>
                </div>
                <div><br>
                </div>
              </div>
            </div>
            <div style="line-height: 1.25;">
              <div style="line-height: 1.25;">
                <div style="line-height: 1.25">
                  <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; color: #000000; width: 50%;">

                      <tr>
                        <td style="width: 50.00%;">
                          <div>
                            <div style="text-align: justify; margin-right: 0.9pt; line-height: 1.25;">Please sign exactly as your name(s) appear(s) hereon. When signing as attorney, executor,
                              administrator, or other fiduciary, please give full title as such. Joint owners should each sign personally. All holders must sign. If a corporation or partnership, please sign in full corporate or partnership name by
                              authorized officer.</div>
                          </div>
                        </td>
                      </tr>

                  </table>
                  <br>
                </div>
              </div>
            </div>
            <div style="line-height: 1.25;">
              <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; color: #000000; width: 100%;">

                  <tr>
                    <td style="width: 25%; border-color: rgb(0, 0, 0); border-style: solid; border-width: 2px;">
                      <div>&#160;</div>
                    </td>
                    <td style="width: 10%; border-top: 2px solid rgb(0, 0, 0); border-right: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0);">
                      <div>&#160;</div>
                    </td>
                    <td style="width: 15%; padding-bottom: 2px;">
                      <div>&#160;</div>
                    </td>
                    <td style="width: 25%; border-color: rgb(0, 0, 0); border-style: solid; border-width: 2px;">
                      <div>&#160;</div>
                    </td>
                    <td style="width: 10%; border-top: 2px solid rgb(0, 0, 0); border-right: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0);">
                      <div>&#160;</div>
                    </td>
                    <td style="width: 10%; padding-bottom: 2px;">
                      <div>&#160;</div>
                    </td>
                    <td style="width: 5%; padding-bottom: 2px;">
                      <div>&#160;</div>
                    </td>
                  </tr>
                  <tr>
                    <td style="width: 25%; border-top: 2px solid rgb(0, 0, 0);">
                      <div>
                        <div style="text-align: left; line-height: 1.25;">Signature [PLEASE SIGN WITHIN BOX]</div>
                      </div>
                    </td>
                    <td style="width: 10%; border-top: 2px solid rgb(0, 0, 0);">
                      <div>&#160;Date</div>
                    </td>
                    <td style="width: 15%;">
                      <div>&#160;</div>
                    </td>
                    <td style="width: 25%; border-top: 2px solid rgb(0, 0, 0);">
                      <div>Signature (Joint Owners)</div>
                    </td>
                    <td style="width: 10%; border-top: 2px solid rgb(0, 0, 0);">
                      <div>Date</div>
                    </td>
                    <td style="width: 10%;">
                      <div>&#160;</div>
                    </td>
                    <td style="width: 5%;">
                      <div>&#160;</div>
                    </td>
                  </tr>

              </table>
            </div>
            <div style="line-height: 1.25">&#160;</div>
          </div>
        </div>
        <div style="line-height: 1.25;"><br style="line-height: 1.25;">
        </div>
        <br>
        <hr align="center" style="border: none; border-bottom: 4px solid black; border-top: 1px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;"></div>
    </div>
    <div style="line-height: 1.25">
      <div style="line-height: 1.25;"><br>
      </div>
      <div style="line-height: 1.25;"> <br>
      </div>
    </div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>image00001.jpg
<TEXT>
begin 644 image00001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 0M!W<# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HILC;$+>E4[6^$TA4\
M8II-BN7J***0PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH AN3BW?Z5QJ74B7Y"M@
M9KJM0N$CA8$XR*XJ1L3LZ^M=5"%TS@Q57E:L=[;/N@4YR<5-7/:#=RS@JYZ5
MT -83CRNQUTI\\;BT445!H%%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4'I144[;86/M0)NR.<\
M1R%2 #6"HXSZU<U&8SS,"<X-4^U>IAHV1X6)J<TM"]8:A]B?&.M=A:2^?"LG
MK7 */G!-=AI%VCQ+&#R*QQ-.VJ.K!5K^ZS7HHHKA/4"BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %1S2K#&7;H*<
M[A!EC@5S&M:J=QBC.5/6M*<'-V1E5JJG&[*6L:D9Y]L;?+WK,#+2[ 3DGK0T
M8'0UZE.DHJQX-:JYRNQ.IXI6V\;: ,48VFMFK&5QV>*9U/TI_6FXP:FUQ-ZF
MWX>NG>X\LMP*ZVN!LIOL<P=3R37;6<QFMU<]Q7F8FFXRN>[@ZJG"Q8HHHKF.
MP**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M0%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !114<LRQ+N8X HL)M+<DIC2*HSD5EW>L0+
M VR0;A7+SZ[<DD*QQ6].A*9SU<3"".FO=<BM3@USNJZHUY@Q,1^-94ER]VV9
M#F@\<+7;#"J)Y-?'2EHA3(\G#DGZTFSG-!XI QKKC%(X93<AW7BDQSBDYH)(
MK0C8?GC'>D]N])GC/>@'CWJ.HA?;O1TXIN2#FC.33M<=AWM0>.*:2<T9)HW
M=[4$8ZTTYS2DD]:+7"PO3K1C%-.:,D]:+7"P\?+UI&'>FDDT9)&*:&.' R:0
MCO2$G%&>,5+3&C1T(8OU-=\O(%>>:1)Y=ZI/2N_MI!)$"#VKR\6O>N>[@)WC
M8FHHHKC/1"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MYQO% 6.AHKG3XML1_P M!6KI^I0ZA'OB8$4 7:*,BB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **1CM4D]JP[CQ/9V\QC9P"* -VBN>/BRQ SO%!\66(&=XH'8Z&B
MN>_X2RQQG>*/^$LL<9\P4!8Z&BN>_P"$LL<9WBI+?Q/9W$PC1P2: L;M%(IW
M*".]+0(**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HJ*>=8(R['@5COXGLT;!<4 ;A('4TPSQCJPKEK
M[Q1;O&?+DYKD+O6[N24F.1L4#2N>K_:(O[XH^T1?WQ7D8UJ]Q_K6IIUF^)P)
M&H'RGKWVB+^^*<)4;H:\A_MF^4#,C5M:3XA9&'G2'\:5Q6/1Z*YN/Q99  &0
M9K3L]6@O,;&!S3$:-%&110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %,,J#JPIMR2L
M#$>E>?:CJ\\,[ 2$<T >A>='_>%'G1_WA7F UZX'60TJZ]..LAH'8].\Z/\
MO"CSH_[PKS#^WK@'/F&@:].#DR'% ['I_G1_WA2B5&. PKRU]=N!D^8:N^'M
M8N+G4U1I"030'*>D44@^Z/I2T$A1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%-
M) ZG%9^HZI'81[V.::BV[(F4E%79>EF2(9=@/K63J>L1V]N6C<$CWKG=7\0B
M^BV0D@_6N<DEG<89R?QKMHX23UD>;B<?&.D#:F\2SSY0]*R9V:9]Q)J- -N.
M]./(V]Z]*%&,5H>-/%SF]6( <4N.<4H^5<'K28SQ6R5C!NXNT9X-+M&<4W:4
MX)HIM"'$ &@@"FT$$4@'$ 4$ 4V@@B@!Q4"C Q3:,$#.: '8&*,#%-HP0,YH
M =M&,T8&,TW-&#C.: '8&,T;1C--S1@]<T,!V!BC Q3:,$C.: '!1B@ &FT
M$]* '  T  TV@ F@!P4&@ 9IM R: ' #-&!FF\]* ": '8&<48&<4TY'% R>
M* '8&<4F!G%(<CBCVH =@9H(&::<BCGI0 X@9H*@4TY%% #B *" *:011VH0
M#F4=J55 %,3Y>M(V<TGJ#' ;GH<!1Q0OR\TNW<P]Z;=T$?B-#PZ2=06O24^Z
M/I7&Z#I#I*D_:NS'05X.)E>9]1@H<L!:***YSM"BBB@ HHHH **** "BBB@
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M)%HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M?ZA/I4E1P_ZA/I4E! 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M/->H6LZSPJRG/%,AD]%%% @HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH @N_^/5_I7E6KG_2FSZUZK=_\>K_2
MO*=8 ^U/GUH*B4. *3[O6A>>M.X[TB@SCFF].3TH[\]*=QWZ4 (< 9K6\+<Z
MJM9'UZ5K^%O^0JN/6C<F1ZJOW1]*6D7[H^E+3)"BBB@ HHHH **** "BBB@
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MI.G/K3LX&:18F>/>CMGO2?[5.SQNH 3/'O5O1L_VK%GU%4_]JKFCG=JL7U%
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M,TBD9!R3[4HR#[4@/\-*>?EH&!)/3I2#(/'2E'R\4$XXH 0DYXJ:S_X_H_\
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M7BXC$.H]#Z;"82-*.NX 8HHHKE.X**** "BBB@ HHHH **** "BBB@ HHHH
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M/2N\ID,****!!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MI:*X)2<G=GK0@HJR"BBBI+"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MC;71>#2D=\23B@EGI=%("&&12TR0HHHH **** "BBB@ HHHH **** "BBB@
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M7KEO_J%^E,ADM%%% @HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MI'CUKURW_P!0OTID,EHHHH$%%%% !1110 4444 %%%% !1110 4444 %%%%
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M)]*DID!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M]67[H^E+2+]T?2EIDA1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% "-]T_2O(?%*,-;8YXS7KS?=/TKR/Q6Q_MEA[UV8
M)VJ'G9DKTC(S\WM2L,\TSFER>E>VCYJPH]:7KS3><<4 D<4Q#NO(H^]TIF6S
MQTI7)7&*&.PI!!IQ.\<4W)(YI%..E*X[,<>F*7&X8%1.WI2[RJTT'*/8X&*4
M'<,5&H:8X7DU8^Q7&W(4YJ6[%*%R Y4TJ!G;'-7X;81ION!@>]2K<Z:ASO7-
M2Y%*#*JZ>\@^]BI1IS6Z^8[ @5S^JZ_+#=%;9_E]JSW\1WTJ&-F/-2Y,U4$=
M)-X@MK=MA49%4;WQ##-;LD8PQZ5S,J2SG<V<FHUMY!U!I.5R^1#VNKG<?WC<
MGUI!+,X_>,3]35F&W+#YA4GV< \BH+32,\)R<BGK&16E]E7 XH\A1UIJ.HG/
ML9ZP-G-2BU8U>5%IRCGVH:L0ZC,W["V<FFFWNHF#0N5P>QK4.:1<GK425T4J
MKB[H]$\!>)PL,=C.Q,G3)->F*P8 @YS7S?%<2V%P)X"0P->P^#_$2WUBB3R
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MC8U>Q1Q<9HZHU%(UZ*8LBL,@BGYKK4DS0****H HHHH **** "BBB@ HHHH
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MW:C0]<,N3UJ,DALFE8;34]O;FZE5,8![U;DDB%&[$2W>X7* FM'3M-"9:Z7
M]ZU8K6'3+4N7!(&:Y+4_%_VAG@5,8XS6#J-[&T*=MSH+N^TZTA;R77>!7'S>
M+;X2N@?Y>U8<K22R%]YYI5A,M*W<V:2'7$\E[(78G)J2WM<GYLU:@LMJY-6D
MA!IV1#:Z$$=J@.<5.% &*DV]J;CG%#(;(R.<=J7 QBI=O:F[?FQ02R/8,4H&
M*?M^;%!7!Q2 ;@&DV"GE<'%!7!Q3N S%+CBG%<&@KB@5A@4"@*!3RN*"N*0Q
M@4 T8 .:>5P*"N!F@!@49S3MH'(I2N!FEVX&:8#-HSF@J.M/V\9I-ORYH>J
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MBBB@"GJ$WE6[<XXKR;4=IU*1\]37IFODBU/TKR^[3-TQSWHL4AI /(I,#\:
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MWXXI!<7D'VI<%AD=*:7'2E$NT;?6@&P^G2D?IQ2;@#CUJ6*!Y9T2-2P)YP*
M3.N\"$$M7>5@^'=&33X%<=6'-;U,AA1110 5'/\ ZA_I4E1S_P"H?Z4 >1:U
M_P A23']ZJG.W'>K>M'&J28_O54[9I%QV#''O1GC'>C/&>]&,C=WH& ''/6C
MH,'K0#D9I.O- %S1_P#D*1Y]:]<M_P#4+]*\CT?G5(\^M>N6_P#J%^E,ADM%
M%% CD/%VDW&H%?)7.*Y=/"]^%QL->K%0>HS2;%_NB@#RD>%]0W<H:!X7U#=]
MPXKU;8O]T4;%_NB@=SREO"U_V0U!<:'>6<?F2J0HKUW8O]T5@^*T4:4V .E
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M%">!0$QQWH'T(=G..U!3!P*F*9XI A'!H C\L8I0H Q4NWM2;#FD21>6*55
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MG%-; Z4,#BHCE>IK0RE<1FQ49IV*9@BK5B;:"#CI12 8ZT $'-/5D6$(%)M
MYH(.<TE-Z&B30;0#FA@",TC=*1<CDTTRTP QS4<D88;N]/8Y/% ..33:N@2*
M3Q$-NR1BM_PYXGFL;R. GY">2:R90).15"5&23<O!K%TEN=="LXL^@[#6([A
M$VN#D>M;D;AUR#7A'AK7G@G2&1R23ZU[)I%R);=3NSD56&JRC.TMCUZ4^9&O
M12 YI:]=.ZN:A1113 **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@#S7QG&OV\,*YP<C/I71>-0?[0![5SZ\I2*0BX?K2;12!
M"#FG?>Z4%7T$^]UH SUI2,]*3[W2@!.LR ^M>MZ",:7%]!7DN,R(.^:]:T$8
MTJ+Z"@F1IT444R1&^Z?I7E7B<9U=OK7JK?=/TKRGQ0,ZNWUH&MS)]NU.QCBD
M XQWHZ<4BPZ<4N,<4@&!BCIQ0 A^4<5L>'P!<+]:Q]I YK8\/C%POUI[BN>H
M6W^H3Z5+45O_ *A?I4M! 4444 %(WW3]*6D;[I^E 'E/B@ :NQ]ZRASSWK5\
M3J?[98^]9.,<]J1:8I]>] YY-'4Y[4$<YH&!'>@?-R:/O'-!'<4 3V0'VV/_
M 'A7KEA_QY1_2O([$;KV,CU%>N6'_'E']*9#19HHHH$1S_ZA_I7D6L<ZK+GU
M->NS_P"H?Z5Y%K )U:7'J:!HJ[1BF]>#2]>*,9&*15A<#IVIO?':E[;>]&.,
M=Z!BXXQVJUH_&JQ8]15/MM[U<T88U6+/J*!,]=@_U"?2I*C@_P!0GTJ2F0%%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !4<_^H?Z5
M)4<_^H?Z4 >1:USJLF?[U5MHVXJSK0SJDF/[U5.V*1<=A.^.U.]J3'&.]&<#
M% Q.G IV,<4!>*;TXH N:0,:I'CUKURW_P!0OTKR/1^-4CSZUZY;_P"H7Z4R
M&2T444""BBB@ HHHH *P/%G_ ""F^E;]8'BS_D%-]* /+UX!/O3QSSWIB*<D
M^]/Q@YI%I@1WH'/)H^\<T$=Z!BXSS36&5R:7J<BD<97(H [#P&?F>N]K@O A
M^9J[VF0PHHHH$1S_ .H?Z5Y%JXSJTN?4UZ[/_J'^E>0ZP,ZM+CU-#&MRMC/%
M-]NU'7BEQQCO2+%QV[4WV[4O;;WHQQCO0 N,<4GEB@<<4<KQ0 G0[10?EXH'
M#<TXC- :"; >:#\O I&XI0,#F@!.G3O1]WD4?=ZTH'>@!.G(HZ<TO0Y-)TYH
M$'3D4>_>CIR:4#)SVH 3W[TJ\G)H(P<]J0_WA0!;T=<ZM&?]JO7H/]0GTKR+
M1>=4C/\ M5Z[!_J$^E,EDE%%% B"[_X]7^E>4ZP,W3GWKU:[_P"/5_I7E.L
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M7P-JUS=VPW$G! KR:490UZ7\/6V6>>V:QK6BN8]'#3=SUB$DH":EJG9W"2J
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MH3Z5)00%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MYYV22>:!UP:]$_X0ZW_R*/\ A#K?_(H"YYWU.#TI02#CM7H?_"'6]'_"'6]
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MQ6KX6XU51623D8K7\+?\A5?K02SU5?NCZ4M(OW1]*6F2%%%% !1110 4444
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MUZ]/_J'^E>0ZR,ZK+]30-%4MQQ1CC/>F_<I^>-U(M"9X]Z,<9[TG^U3L\;J
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MXH)D>K+]T?2EIJ$,@QZ4ZF2%%%% !1110 4444 %%%% !1110 4444 %%%%
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M+MD(!8USF?3I2;BDBR(>1038]JBD66,.IX-/K@]%\4':L<QP!75P:S:3 !9
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MK@-8UJ74G:-A\H/% TC*\T2)O;ECUII.>E-5 .*> !TI%V =,=Z#Z#K1TY%
M]>]  ,=#UH+!3S0?7O3& .,]<T"L:^AV$DE_'*!\N:]5A&(4'M7,>%K)#9))
MWKJ0,#%,EBT444"(YQNA8>U>9^)8?)G)(ZFO3R,C%<#XWB5'4T#1R*^].^M)
M@;101GK2+#Z]*7COTI.U)UX/2@ ^O2IK><VLHD4XYJ+'&*:P+<=J!-'J_AZY
M-SIZNQR<5KUY[X=UU;-5AD;"5W=M=Q748>-@0:9!/1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M[U-B.N3QJ8HE7;G%/_X3<X^Y7&>6.XH" 'GI0*QT&L>(&U2$(ORU@KOZ,V:
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !113&8#J:F4E'<!V:,U7:YC
M'\0_.J=UJ*QCY6'YUR5,9"GJQV-3(JK<7D<'WC6&^M.%.*S;C47N3\W:N.MF
MD.7W0.DDU6%1]ZLN[U7GY7K%:5I.IZ4S);J:\:MCIRV97,C1.I2,/OFL^6:1
MWR334IQ%<3K5'NR)/L-WG'S'BF@8.3TH^\<&G=1@]*EW;)NV-QSN[4F5+4YN
MF!3=@"YJU%;DNXW_ ):>U(W^LSVI:0C(IO4!Q(;I49&#[4Y%P<4]P!0M &<
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M7;O=5]:TBK@EJ=+X..2U=E7.^'+/[.F[&,UT5?4X-6I(Z(JR"BBBNH84444
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MJLB*2/:MJ.)(EVH !3Z*!!1110 4444 %%%% !1110 5!<6L5PN'4'ZBIZ*
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MQU/Y5UU% 7.1_P"$*M\=3^5:6G>'8+'H ?J*W**!$:P1KT1?RJ2BB@ HHHH
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M_E1Y$7]Q?RJ2B@!@AB'1%_*G!0.@Q2T4 %%%% !1110 4444 %%%% !1110
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M23076VW?CVH [W>O]X4ZO*K?Q1?-=1HSG!->FV4AEM(W/4B@"Q1110 4444
M%%%1S,5C)'I0 _>HZD4@=3T85YUK?B&\MK]HXV.T4>'_ !!>W>J+'(Q*DT#L
M>CT4@^Z/I2T""BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M:.M%%2(/:FD_PTNX9P*7C/O5Q 9[4>U.;'XT@(Q[U38K#3QQ3"N#4A(S[TG
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M_A.3MSLH [ZBN?T37UU),G@UO@Y&: %I-H]*CN9?)@:3T%<5-XV\N=TV_=-
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M '6O6P.$YI7>PTD6;6W6WB"J,<58HHKZ**459%A1113 **** "BBB@ HHHH
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MC)#;X@;#>U<%]IN)US,Q(]ZU=>U%IKZ2%CP#6,KEW\M1FDQH3:N[@<4-'DY
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MLTQ(FT2U2>^5&&>:]1TRT6UA 48KS;PPV=77/K7JT?W%^E -CJ***!!1110
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MCA574$@>E7TC6-<*,5]#@\ HZS0[$5M;+;QA0*L445ZT8J*LAA1115 %%%%
M!1110 4444 %%%% !1110 4444 %<!XPO62Y\H=#7?UYKXTYOQ0-'/)&'?:>
MAKOO#$EM9VNTR*/QK@0"%]Z037"'Y9"!]:!GK%]?6SV<@\Q3D>M>47J#[7(5
MY!-/-W<E<&5OSJ(' .[DF@-CL? B@%J[RO-/"NHK8S;7_B->CPR"6(..XH$]
MSEO&W_'D*\\4X>/'K7H/C7BT&:\_CC/F1L?6@#UO0/\ D%1?05=NO]2WTJGH
M/_(+B^@J[<MMB.?2@.IY5KW&IM]:D\,'_B<+]:C\0C_B9LW;-2>%T)U=6]Z0
M,]67[H^E<_XCTY)K5YCU KH%^Z/I6;KS;=+E/L:8CR.4 %_8UV7A^4QZ%*P[
M"N-<&620CCFNITJ=8]$DC/4BD5>YS]W<FZF8,>AJ73+$SW<; $X-49$(E8^]
M=?X*C29FW '%-;E,[BR79:1KZ"F7EXEM&2S 'W-6>$3Z5PGC.[?<!&Y'T-!F
M9VL^();N=H0?E'I7//EVRS&B-3G>QR:N66GR:I-Y<8P105LBFOSG:6.!3L ?
M+G(KH6\&W*IG-8EY:/9RF)NHH#8T/#" :POUKU7_ )9_A7E7A?\ Y"Z_6O5?
M^6?X4"9Y7XIYU5OK531AC58L>HJWXIYU5OK531N-4BSZB@%L>NP?ZA/I6=KW
M_(.D^E:,'^H3Z5FZ_P Z;)]*!'DTGRROCUKL_ @ +&N-*XD?/K79>! 0ST%O
M8[.__P"/*3Z5Y'>*!>2?6O7+_P#X\I/I7D5X=M[)GUH)1  !*A]Z]:T+_D%Q
M?05Y$0?-0^]>N:!_R"HOH*!LU****"1#T-<#XI4&5N:[X]#7 >*E)E:@J)R0
MZ8I#&N/O8- !7DUIV&@3ZH/,C/ H RP-O\7ZT["GO70MX+NCT-*/!=UCK0!S
M]HJ_;X^?XA7KUKQIB?[M<':^#;J*Z20G@&O0(HS#9*AZ@4";N>=^*3F;GUK"
MMAF\A^M;OBL9FX]:P[7_ (_(OK0&IZ]IO_'E'_NBH-7 -LWTJ?3O^/*/_=%5
M]9S]F;Z4"/++_F]D'O6WX,)_M BL2_7-V_UK<\&?\?Y%!?0])'04M(.@I:"
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MKUZ&6<VL@L8]EHL;P*94^:MJ"V2! JC@5,% Z"EKV*.&C35@"BBBNH HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** (YY!'$6)Z5YEXHG6>\RISBO
M0-;<QZ9*PZ@&O)99VFE=F[&@I#%$DC!%&6/2KBZ/?LN?*;\JMZ#:F:^C<KD
M^E>H101")?W:]/2@&>2#1[_/,3?E45Q:36V/.4K]:]B-O%_SS7\JX;QS&JLN
MU0/I0*YRMHY%[%CUKUW3CFRC_P!T5Y!:<7<7UKUW374V<8!_A% CG?&PS9BO
M/E<[XQVS7H7C4_Z&*\]4$LI]#1<H]<T#_D%1?05?G"F,[O2N7\/:NBVZ12,
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MI@CA[]LW3X]:V_!F/MY]:YUF+YD/4UT/@L?\3 FD4STL=!2T@Z"EID!1110
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M;';*,?6@?0$NKA3A9& ^M(\TSG]XQ8>YH S]WO6OH^E/.S-<(=F.,TAIF46
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MBBD(8?E.?6@#O2[>>: "#[4 -(QS1MW<TI!)]J3E>>U ";=O-(1NYI2"1FD
M/7M5(5@ [T$;AF@\]*,'%4A#*51FEVY&::,]J8!WIK#-.I#36@F&.*;][BE/
M/2DY[5I"-Q";.:4CM2*&=MH!K0CT>:10P/6NJ&#K3V1+9FMDC:*(87FD\K%;
MUIHS)("_-:T=A C;@@S7K87+)/XQ&''H!:,<UI6FEB!0#SBM4* ,"EKV:>7T
MHK81$L*CM4@&*6BNV-.,=A!1115@%%%% !1110 4444 %%%% !1110 4444
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MI:* N%,F3S(F3U%/HH Y>3PP'D9L]35O2]#%A-OS6[10 5F:MIW]H1!*TZ*
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MLO\ CTC^E>3Z9C[6GUKUBR_X](_I0#)Z***!!7/>*=0EL+4-$<&NAKDO&_\
MQY"@#B[K5[G4$VRL2*HLWEKQ306"?*,U<TS3Y-0NEC((R:$AHZKPIIROMN2O
M/K7=#I6=H^GC3[-8NO%:5 ,****!!1110 4444 %%%% !1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ K)U^VENK!DB'S&M:D(!ZT >6'PO?')V'-3Z5X;O(-0CD=#@&O2]B_
MW11L4=A0%Q(AMB4'L*?110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 4-8@:XT^
M2-!R17FS>%;[>Y"'DUZQUINQ?[HH!'FNF>'+V*Y5G0X!KT:V0I;HIZ@5)L4?
MPBG4 %%%% !7-^*].FO[4+",FNDI" >HS0!P6A^&I$<?:8\CWKKK;2+:V8,D
M8!%7PH'0"EH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M$%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !6?J,9=.*T*@G7<AKC
MQT.>DT5'<Y_ ^Z:3[I]J<XQ.PH(#'%?GF(I^SFTSL3T$X848&*3&#BEZ\5SI
M@F(/TH/MTH[X[4'CBGH5T$XQ32!MIVVDXW8IHS$1@!S2[0_*TDB8/%&[8N!W
MHA%MV0VQ"^.%IT4#3M\H^M36-H9B2PZUKVUDL'(KZ# 97*;YI;&4IHKPZ9'@
M%AS6A'"L:@ 5(!BEKZBA@Z=-:(Q<FP%%%%=JT)"BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MCFG(5$"K@"GT45];&*BK(Q"BBBJ **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH *I7L9:(X%7:9(,J:YL5252FT
M5%V9SA3;P:" 1BI[I/WY%0D8XK\^Q='V4VCK3NKC<8%.C 8[?6DQFK5I:[G#
M9I83#RJU%8).R-"SMQ$G JY34&% IU?H>&I*E321QMW84445T""BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ I#TI:*35P,Z^B 0MCFLC)+5T<T8="#6#<)LF(%?(YWA;/F1TTI:6&<M\
MJ]:UM/C94^:L^T"F89ZUN1J *TR.A=<S)J2'BEHHKZI*Q@%%%%, HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** $/2LJ]M\$R5K56NXS)'@5Q8R@JM-HJ+LS+LHB9@];:]*K6D'EI
MR*MUCEN%="%F$G=A1117IDA1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !28I:*+ %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
=%% !1110 4444 %%%% !1110 4444 %%%% '_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>scan.jpg
<TEXT>
begin 644 scan.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  (! 0(! 0(" @(" @(" P4# P,#
M P8$! ,%!P8'!P<&!P<("0L)" @*" <'"@T*"@L,# P,!PD.#PT,#@L,# S_
MVP!# 0(" @,# P8# P8," <(# P,# P,# P,# P,# P,# P,# P,# P,# P,
M# P,# P,# P,# P,# P,# P,# P,# S_P  1" !, 1 # 2(  A$! Q$!_\0
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M6H?\$]?V1=3^*.G>'K?Q5)HVIZ?;2Z7+.UN;N*XNHX75)%#;'P^5)5AD<J:
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M_AZ9^S1_T<!\&?\ PLM/_P#CM(#S'_@X"_Y0^_&O_L'V7_IRM*]@_P""<?\
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@% !1110 4444 %%%% !1110 4444 %%%% !1110!_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
